Patent Application
20250230141
The present invention relates to substituted bicyclic compounds, particularly, substituted fused bicyclic compounds having agonist activity.
Orexin is a neuropeptide synthesized and released by a subpopulation of neurons within the lateral hypothalamus and its surrounding regions. It consists of two subtypes: orexin A and orexin B. Orexin A and orexin B bind to orexin receptors. Orexin receptors are G protein-coupled receptors expressed preferentially in the brain. There are two subtypes (type 1 and type 2) of orexin receptors (Cell, Vol. 92, 573-585, 1998). Activation of orexin receptors is known to be important for a variety of central nervous system functions, such as maintenance of wakefulness, energy homeostasis, reward processing and motivation (Saper et al, TRENDS in Neuroscience 2001: Yamanaka et al., Neuron 2003: Sakurai, Nature Reviews Neuroscience 2014).
Narcolepsy is a neurological disease that results in excessive daytime sleepiness, sudden bouts of muscular paralysis (cataplexy), and disrupted sleep patterns (Mahoney et al., Nature Reviews Neuroscience, 2019). It is known that narcolepsy is caused by the degeneration of orexin neurons. Narcoleptic symptoms can be modeled in transgenic mice engineered to degenerate orexin neurons, and their symptoms can be reversed by intraventricular administration of orexin peptides (Proc. Natl. Acad. Sci. USA, Vol. 101, 4649-4654, 2004). Studies of orexin-2 receptor knockout mice have suggested that the orexin-2 receptor plays a preferential role in maintaining wakefulness (Cell, Vol. 98, 437-451, 1999, Neuron, Vol. 38, 715-730, 2003). As such, orexin-2 receptor agonists can be therapeutic agents for narcolepsy or other disorders exhibiting excessive daytime sleepiness, such as Parkinson's disease (CNS Drugs, Vol. 27, 83-90, 2013; Brain, Vol. 130, 2007, 1586-1595).
A compound having agonist activity at the orexin-2 receptor is hypothesized to be useful as a novel therapeutic agent for narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, disturbance of consciousness such as coma and the like, narcolepsy syndrome, hypersomnolence syndrome characterized by hypersomnia (e.g., in Parkinson's disease, Guillain-Barre syndrome or Kleine Levin syndrome), Alzheimer's disease, obesity, insulin resistance syndrome, cardiac failure, diseases related to bone loss, or sepsis and the like. (Cell Metabolism, Vol. 9, 64-76, 2009; Neuroscience, Vol. 121, 855-863, 2003; Respiration, Vol. 71, 575-579, 2004; Peptides, Vol. 23, 1683-1688, 2002; WO 2015/073707; Journal of the American College of Cardiology, Vol. 66, 2015, pages 2522-2533; WO 2015/048091; WO 2015/147240).
Some compounds having orexin-2 receptor agonist activity have been reported (U.S. Pat. No. 8,258,163; WO 2015/088000; WO 2014/198880; Journal of Medicinal Chemistry, Vol. 58, pages 7931-7937; US 20190040010; US 20190031611; US 20170226137). However, it is considered that these compounds are not satisfactory, for example, in terms of activity, pharmacokinetics, permeability into the brain/central nervous system or safety, and the development of an improved compound having orexin-2 receptor agonist activity is desired.
The present invention aims to provide fused bicyclic compounds having orexin-2 receptor agonist activity.
Accordingly, in an initial aspect, the present invention provides a compound represented by Formula I-A or a pharmaceutically acceptable salt thereof:
wherein:
In one embodiment, provided herein are compounds of Formula I-A having the structure of Formula I or a pharmaceutically acceptable salt thereof:
wherein:
Also provided herein is a pharmaceutical composition comprising a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
In another aspect, provided herein is a method of treating narcolepsy in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In another aspect, provided herein is a method of treating cataplexy in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
Provided herein are compounds, e.g., the compounds of Formula I-A, or I, or pharmaceutically acceptable salts thereof, that are useful in the treatment of narcolepsy or cataplexy in a subject.
In a non-limiting aspect, these compounds may modulate the orexin-2 receptor. In a particular embodiment, the compounds provided herein are considered orexin-2 agonists. As such, in one aspect, the compounds provided herein are useful in treatment of narcolepsy in a subject by acting as an agonist of the orexin-2 receptor.
Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.
Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, and peptide chemistry are those well-known and commonly employed in the art.
As used herein, the articles “a” and “an” refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. Furthermore, use of the term “including” as well as other forms, such as “include,” “includes,” and “included,” is not limiting.
As used herein, the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. As used herein when referring to a measurable value such as an amount, a temporal duration, and the like, the term “about” is meant to encompass variations of ±20% or ±10%, including ±5%, ±1%, and ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
As used to herein, the term “EC50” refers to the concentration of a compound required to achieve an effect that is 50% of the maximal observed effect of a compound.
The term “agonist,” as used herein, refers to a compound that, when contacted with a target of interest (e.g., the orexin-2 receptor), causes an increase in the magnitude of a certain activity or function of the target compared to the magnitude of the activity or function observed in the absence of the agonist.
The term “treat,” “treated,” “treating,” or “treatment” includes the diminishment or alleviation of at least one symptom associated or caused by the state, disorder or disease being treated. In certain embodiments, the treatment comprises bringing into contact with the orexin-2 receptor an effective amount of a compound of the invention for conditions related to narcolepsy or cataplexy.
As used herein, the term “prevent” or “prevention” means no disorder or disease development if none had occurred, or no further disorder or disease development if there had already been development of the disorder or disease. Also considered is the ability of one to prevent some or all of the symptoms associated with the disorder or disease.
As used herein, the term “patient,” “individual” or “subject” refers to a human or a non-human mammal. Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline and murine mammals. Preferably, the patient, subject, or individual is human.
As used herein, the terms “effective amount,” “pharmaceutically effective amount,” and “therapeutically effective amount” refer to a nontoxic but sufficient amount of an agent to provide the desired biological result. That result may be reduction or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. An appropriate therapeutic amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
As used herein, the term “pharmaceutically acceptable salt” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
The phrase “pharmaceutically acceptable salt” is not limited to a mono, or 1:1, salt. For example, “pharmaceutically acceptable salt” also includes bis-salts, such as a bis-hydrochloride salt. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
As used herein, the term “composition” or “pharmaceutical composition” refers to a mixture of at least one compound useful within the invention with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.
As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the patient. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations.
As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the invention and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions. The “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound useful within the invention. Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the invention are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
As used herein, the term “alkyl,” by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon having the number of carbon atoms designated (i.e., C1-6 alkyl means an alkyl having one to six carbon atoms) and includes straight and branched chains. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, and hexyl. Other examples of C1-C6-alkyl include ethyl, methyl, isopropyl, isobutyl, n-pentyl, and n-hexyl.
As used herein, the term “halo” or “halogen” alone or as part of another substituent means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom, preferably, fluorine, chlorine, or bromine, more preferably, fluorine or chlorine.
As used herein, the term “alkylene” refers to divalent aliphatic hydrocarbyl groups, for example, having from 1 to 4 carbon atoms that are either straight-chained or branched. This term includes, by way of example, methylene (—CH2—), ethylene (—CH2CH2—), n-propylene (—CH2CH2CH2—), iso-propylene (—CH2CH(CH3)—), and the like.
As used herein, the term “alkenyl” denotes a monovalent group derived from a hydrocarbon moiety containing at least two carbon atoms and at least one carbon-carbon double bond. The double bond may or may not be the point of attachment to another group. Alkenyl groups (e.g., C2-C8-alkenyl) include, but are not limited to, for example, ethenyl, propenyl, prop-1-en-2-yl, butenyl, 1-methyl-2-buten-1-yl, heptenyl, octenyl and the like.
As used herein, the term “alkynyl” denotes a monovalent group derived from a hydrocarbon moiety containing at least two carbon atoms and at least one carbon-carbon triple bond. The triple bond may or may not be the point of attachment to another group. Alkynyl groups (e.g., C2-C8-alkynyl) include, but are not limited to, for example, ethynyl, propynyl, prop-1-yn-2-yl, butynyl, 1-methyl-2-butyn-1-yl, heptynyl, octynyl and the like.
As used herein, the term “alkoxy,” refers to the group —O-alkyl, wherein alkyl is as defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, t-butoxy and the like.
As used herein, the term “cycloalkyl” means a non-aromatic carbocyclic system that is partially or fully saturated having 1, 2 or 3 rings wherein such rings may be fused. The term “fused” means that a second ring is present (i.e., attached or formed) by having two adjacent atoms in common (i.e., shared) with the first ring. Cycloalkyl also includes bicyclic structures that may be bridged or spirocyclic in nature with each individual ring within the bicycle varying from 3-8 atoms. The term “cycloalkyl” includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[3.1.0]hexyl, spiro[3.3]heptanyl, and bicyclo[1.1.1]pentyl.
As used herein, the term “heterocyclyl” means a non-aromatic carbocyclic system containing 1, 2, 3 or 4 heteroatoms selected independently from N, O, and S and having 1, 2 or 3 rings wherein such rings may be fused, wherein fused is defined above. Heterocyclyl also includes bicyclic structures that may be bridged or spirocyclic in nature with each individual ring within the bicycle varying from 3-8 atoms, and containing 0, 1, or 2 N, O, or S atoms. The term “heterocyclyl” includes cyclic esters (i.e., lactones) and cyclic amides (i.e., lactams) and also specifically includes, but is not limited to, epoxidyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl (i.e., oxanyl), pyranyl, dioxanyl, aziridinyl, azetidinyl, pyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, oxazolidinyl, thiazolidinyl, piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1,3-oxazinanyl, 1,3-thiazinanyl, and the like. For example, the term “heterocyclyl” can include 4- to 10-membered heterocyclyl, 4- to 7-membered heterocyclyl, 5- to 10-membered heterocyclyl, 6- to 10-membered heterocyclyl, 4- to 6-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6-membered heterocyclyl, 7-membered heterocyclyl, 8-membered heterocyclyl, 9-membered heterocyclyl, or 10-membered heterocyclyl.
As used herein, the term “aromatic” refers to a carbocycle or heterocycle with one or more polyunsaturated rings and having aromatic character, i.e., having (4n+2) delocalized π (pi) electrons, where n is an integer.
As used herein, the term “aryl” means an aromatic carbocyclic system containing 1, 2 or 3 rings, wherein such rings may be fused, wherein fused is defined above. If the rings are fused, one of the rings must be fully unsaturated and the fused ring(s) may be fully saturated, partially unsaturated or fully unsaturated. The term “aryl” includes, but is not limited to, phenyl, naphthyl, indanyl, and 1,2,3,4-tetrahydronaphthalenyl. For example, the term “aryl” can include C6-C10 aryl, C6-C8 aryl, or C6 aryl (i.e., phenyl).
As used herein, the term “heteroaryl” means an aromatic carbocyclic system containing 1, 2, 3, or 4 heteroatoms selected independently from N, O, and S and having 1, 2, or 3 rings wherein such rings may be fused, wherein fused is defined above. The term “heteroaryl” includes, but is not limited to, furanyl, thiophenyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and the like. For example, the term “heteroaryl” can include 5- to 10-membered heteroaryl, 5- to 8-membered heteroaryl, 5- to 6-membered heteroaryl, 6- to 10-membered heteroaryl, 6- to 8-membered heteroaryl, 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 9-membered heteroaryl, or 10-membered heteroaryl.
It is to be understood that if an aryl, heteroaryl, cycloalkyl, or heterocyclyl moiety may be bonded or otherwise attached to a designated moiety through differing ring atoms (i.e., shown or described without denotation of a specific point of attachment), then all possible points are intended, whether through a carbon atom or, for example, a trivalent nitrogen atom. For example, the term “pyridinyl” means 2-, 3- or 4-pyridinyl, the term “thiophenyl” means 2- or 3-thiophenyl, and so forth.
As used herein, the term “substituted” means that an atom or group of atoms has replaced hydrogen as the substituent attached to another group.
Accordingly, in an initial aspect, the present invention provides a compound represented by Formula I-A or a pharmaceutically acceptable salt thereof:
wherein:
In one embodiment, provided herein are compounds of Formula I-A having the structure of Formula I or a pharmaceutically acceptable salt thereof:
wherein:
In one embodiment of Formula (I), ring A is selected from the group consisting of: 4- to 7-membered heterocyclyl, C6-C10 aryl and 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl, C6-C10 aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is selected from the group consisting of: C3-C8 cycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is selected from the group consisting of: C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is selected from the group consisting of: C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, and C6-C10 aryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is selected from the group consisting of: C6-C10 aryl and 5- to 7-membered heteroaryl, wherein the C6-C10 aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is selected from the group consisting of: C3-C8 cycloalkyl and 4- to 7-membered heterocyclyl, wherein the C3-C8 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is selected from the group consisting of: C3-C8 cycloalkyl and C6-C10 aryl, wherein the C3-C8 cycloalkyl or C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is selected from the group consisting of: 4- to 7-membered heterocyclyl and C6-C10 aryl, wherein the 4- to 7-membered heterocyclyl or C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is selected from the group consisting of: 4- to 7-membered heterocyclyl and 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is 4- to 7-membered heterocyclyl, wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is C6-C10 aryl, wherein the C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is 5- to 7-membered heteroaryl wherein the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is selected from the group consisting of: 4- to 7-membered heterocyclyl, C6-C10 aryl and 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl, C6-C10 aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is selected from the group consisting of: C3-C8 cycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is selected from the group consisting of: C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is selected from the group consisting of: C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, and C6-C10 aryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is selected from the group consisting of: C6-C10 aryl and 5- to 7-membered heteroaryl, wherein the C6-C10 aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is selected from the group consisting of: C3-C8 cycloalkyl and 4- to 7-membered heterocyclyl, wherein the C3-C8 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is selected from the group consisting of: C3-C8 cycloalkyl and C6-C10 aryl, wherein the C3-C8 cycloalkyl or C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is selected from the group consisting of: 4- to 7-membered heterocyclyl and C6-C10 aryl, wherein the 4- to 7-membered heterocyclyl or C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is selected from the group consisting of: 4- to 7-membered heterocyclyl and 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is 4- to 7-membered heterocyclyl, wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is C6-C10 aryl, wherein the C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring B is 5- to 7-membered heteroaryl wherein the 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A and ring B are each, independently, selected from the group consisting of: 4- to 7-membered heterocyclyl, C6-C10 aryl and 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl, C6-C10 aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A and ring B are each, independently, selected from the group consisting of: C3-C8 cycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A and ring B are each, independently, selected from the group consisting of: C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, and 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A and ring B are each, independently, selected from the group consisting of: C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, and C6-C10 aryl, wherein the C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A and ring B are each, independently, selected from the group consisting of: C6-C10 aryl and 5- to 7-membered heteroaryl, wherein the C6-C10 aryl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A and ring B are each, independently, selected from the group consisting of: C3-C8 cycloalkyl and 4- to 7-membered heterocyclyl, wherein the C3-C8 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A and ring B are each, independently, selected from the group consisting of: C3-C8 cycloalkyl and C6-C10 aryl, wherein the C3-C8 cycloalkyl or C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A and ring B are each, independently, selected from the group consisting of: 4- to 7-membered heterocyclyl and C6-C10 aryl, wherein the 4- to 7-membered heterocyclyl or C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A and ring B are each, independently, selected from the group consisting of: 4- to 7-membered heterocyclyl and 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is 5- to 7-membered heteroaryl and ring B is C6-C10 aryl, wherein the 5- to 7-membered heteroaryl and C6-C10 aryl are each, independently, unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is 5- to 7-membered heteroaryl and ring B is 5- to 7-membered heteroaryl, wherein each 5- to 7-membered heteroaryl, independently, is unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is 4- to 7-membered heterocyclyl and ring B is C6-C10 aryl, wherein the 4- to 7-membered heterocyclyl and C6-C10 aryl are each, independently, unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is 4- to 7-membered heterocyclyl and ring B is 5- to 7-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl and 5- to 7-membered heteroaryl are each, independently, unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is C3-C8 cycloalkyl and ring B is C6-C10 aryl, wherein the C3-C8 cycloalkyl and C6-C10 aryl are each, independently, unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), ring A is C3-C8 cycloalkyl and ring B is 5- to 7-membered heteroaryl, wherein the C3-C8 cycloalkyl and 5- to 7-membered heteroaryl are each, independently, unsubstituted or substituted with one or more halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I),
is selected from the group consisting of benzoimidazolyl, 1H-pyrazolo[3,4-c]pyridinyl, imidazo[1,5-a]pyridinyl, indolyl, isoindolyl, indolinyl, indazolyl, isoindazolyl, benzothiazolyl, purinyl, benzofuranyl, benzoisoxazolyl, benzoisothiazolyl, isobenzofuranyl, benzothiofuranyl, indoleninyl, pyrano[3,4-b]-pyrrolyl, indoxazinyl, benzoxazolyl, anthranilyl, and indolizinyl, wherein the benzoimidazolyl, 1H-pyrazolo[3,4-c]pyridinyl, imidazo[1,5-a]pyridinyl, indolyl, isoindolyl, indolinyl, indazolyl, isoindazolyl, benzothiazolyl, purinyl, benzofuranyl, benzoisoxazolyl, benzoisothiazolyl, isobenzofuranyl, benzothiofuranyl, indoleninyl, pyrano[3,4-b]-pyrrolyl, indoxazinyl, benzoxazolyl, anthranilyl, and indolizinyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is benzoimidazolyl, wherein the benzoimidazolyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is 1H-pyrazolo[3,4-c]pyridinyl, wherein the 1H-pyrazolo[3,4-c]pyridinyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is imidazo[1,5-a]pyridinyl, wherein the imidazo[1,5-a]pyridinyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is indolyl, wherein the indolyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is isoindolyl, wherein the isoindolyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is indolinyl, wherein the indolinyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is indazolyl, wherein the indazolyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is isoindazolyl, wherein the isoindazolyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is benzothiazolyl, wherein the benzothiazolyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is purinyl, wherein the purinyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is benzofuranyl, wherein the benzofuranyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is benzoisoxazolyl, wherein the benzoisoxazolyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is benzoisothiazolyl, wherein the benzoisothiazolyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is isobenzofuranyl, wherein the isobenzofuranyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is benzothiofuranyl, wherein the benzothiofuranyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is indoleninyl, wherein the indoleninyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is pyrano[3,4-b]-pyrrolyl, wherein the pyrano[3,4-b]-pyrrolyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is indoxazinyl, wherein the indoxazinyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is benzoxazolyl, wherein the benzoxazolyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is anthranilyl, wherein the anthranilyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is indolizinyl, wherein the indolizinyl is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1-2 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1-2 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1 substituent selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1-2 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1-2 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1-2 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1-2 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or substituted with 1-3 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1-2 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1-2 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1-2 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1 substituent selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1-2 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I),
is
which is unsubstituted or further substituted with 1-2 substituents selected from halogen, hydroxyl, C1-C3 alkoxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with 1-3 halogen or deuterium atoms.
In another embodiment of Formula (I), p is 0. In another embodiment of Formula (I), p is 1. In another embodiment of Formula (I), p is 2. In another embodiment of Formula (I), p is 3. In another embodiment of Formula (I), p is 4. In another embodiment of Formula (I), p is 0, 1 or 2. In another embodiment of Formula (I), p is 0 or 1.
In another embodiment of Formula (I), p is 1 and R9 is deuterium. In another embodiment of Formula (I), p is 1 and R9 is halogen. In another embodiment of Formula (I), p is 1 and R9 is fluorine. In another embodiment of Formula (I), p is 1 and R9 is hydroxyl. In another embodiment of Formula (I), p is 1 and R9 is cyano. In another embodiment of Formula (I), p is 2 and each R9 is hydroxyl. In another embodiment of Formula (I), p is 2 and each R9 is halogen. In another embodiment of Formula (I), p is 2 and each R9 is fluorine.
In another embodiment of Formula (I), E is NRaRb. In another embodiment of Formula (I), E is C1-C3 alkylene-NRaRb. In another embodiment of Formula (I), E is unsubstituted C1-C3 alkyl, unsubstituted C2-C4 alkenyl or unsubstituted C2-C4 alkynyl. In another embodiment of Formula (I), E is C1-C3 alkyl, C2-C4 alkenyl or C2-C4 alkynyl substituted with one or more halogen, hydroxyl, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of Formula (I), E is unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), E is C1-C3 alkyl substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl.
In another embodiment of Formula (I), E is unsubstituted C3-C8 cycloalkyl. In another embodiment of Formula (I), E is C3-C8 cycloalkyl substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of Formula (I), E is unsubstituted C1-C3 alkylene-(C3-C8 cycloalkyl). In another embodiment of Formula (I), E is C1-C3 alkylene-(C3-C8 cycloalkyl) substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of Formula (I), E is unsubstituted 4- to 10-membered heterocyclyl. In another embodiment of Formula (I), E is 4- to 10-membered heterocyclyl substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of Formula (I), E is unsubstituted C1-C3 alkylene-(4- to 10-membered heterocyclyl). In another embodiment of Formula (I), E is C1-C3 alkylene-(4- to 10-membered heterocyclyl) substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of Formula (I), E is unsubstituted C6-C10 aryl. In another embodiment of Formula (I), E is C6-C10 aryl substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of Formula (I), E is unsubstituted C1-C3 alkylene-(C6-C10 aryl). In another embodiment of Formula (I), E is C1-C3 alkylene-(C6-C10 aryl) substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of Formula (I), E is unsubstituted 5- to 7-membered heteroaryl. In another embodiment of Formula (I), E is 5- to 7-membered heteroaryl substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of Formula (I), E is unsubstituted C1-C3 alkylene-(5- to 7-membered heteroaryl). In another embodiment of Formula (I), E is C1-C3 alkylene-(5- to 7-membered heteroaryl) substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl.
In another embodiment of Formula (I), E is C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, or C1-C3 alkylene-(4- to 10-membered heterocyclyl), wherein the C1-C3alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, or C1-C3 alkylene-(4- to 10-membered heterocyclyl) is unsubstituted or substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl.
In another embodiment of Formula (I), E is C1-C3 alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, or C1-C3 alkylene-(4- to 10-membered heterocyclyl), wherein the C1-C3alkyl, C3-C8 cycloalkyl, C1-C3 alkylene-(C3-C8 cycloalkyl), 4- to 10-membered heterocyclyl, or C1-C3 alkylene-(4- to 10-membered heterocyclyl) is unsubstituted or substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl.
In another embodiment of Formula (I), E is C1-C3 alkyl, C3-C8 cycloalkyl, or C1-C3 alkylene-(C3-C8 cycloalkyl), wherein the C1-C3alkyl, C3-C8 cycloalkyl, or C1-C3 alkylene-(C3-C8 cycloalkyl) is unsubstituted or substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl.
In another embodiment of Formula (I), E is methyl. In another embodiment of Formula (I), E is methyl substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl. In another embodiment of Formula (I), E is CF3. In another embodiment of Formula (I), E is CHF2. In another embodiment of Formula (I), E is CH2F. In another embodiment of Formula (I), E is NH(CH3). In another embodiment of Formula (I), E is N(CH3)2.
In another embodiment of Formula (I), E is C6-C10 aryl, C1-C3 alkylene-(C6-C10 aryl), 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl). In another embodiment of Formula (I), E is unsubstituted C6-C10 aryl or C1-C3 alkylene-(C6-C10 aryl). In another embodiment of Formula (I), E is C6-C10 aryl or C1-C3 alkylene-(C6-C10 aryl) substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl.
In another embodiment of Formula (I), E is 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl). In another embodiment of Formula (I), E is unsubstituted 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl). In another embodiment of Formula (I), E is 5- to 7-membered heteroaryl or C1-C3 alkylene-(5- to 7-membered heteroaryl) substituted with one or more halogen, hydroxyl, NRcRd, CF3, CHF2, CH2F, C1-C3 alkyl, or C1-C3 alkoxyl.
In another embodiment of Formula (I), Y is S(═O)2. In another embodiment of Formula (I), Y is C(═O). In another embodiment of Formula (I), Y is S(═O)(=NRe).
In another embodiment of Formula (I), X is N. In another embodiment of Formula (I), X is CH.
In another embodiment of Formula (I), R1 is selected from the group consisting of C(═O)—C1-C4 alkyl, C(═O)—C1-C4 alkoxyl, C(═O)—(CRcRd)n—C3-C8 cycloalkyl, C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl), C(═O)—(CReRd)n—(C6-C10 aryl), and C(═O)—(CRcRd)n-(5- to 10-membered heteroaryl), wherein the C1-C4 alkyl, C1-C4 alkoxyl, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is selected from the group consisting of C(═O)—C1-C4 alkyl, C(═O)—C1-C4 alkoxyl, and C(═O)—(CRcRd)n—C3-C8 cycloalkyl, wherein the C1-C4 alkyl, C1-C4 alkoxyl, or C3-C8 cycloalkyl, is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is selected from the group consisting of C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl), C(═O)—(CReRd)n—(C6-C10 aryl), and C(═O)—(CReRd)n-(5- to 10-membered heteroaryl), wherein the 4- to 7-membered heterocyclyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—C1-C4 alkyl, wherein the C1-C4 alkyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—C1-C4 alkoxyl, wherein the C1-C4 alkoxyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl), wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl), wherein the C6-C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 10-membered heteroaryl), wherein the 5- to 10-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heterocyclyl), wherein the 5- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 6-membered heterocyclyl), wherein the 5- to 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl), wherein the 5-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl), wherein the 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl), wherein the C6 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C8 aryl), wherein the C8 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C10 aryl), wherein the C10 aryl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 6-membered heteroaryl), wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl), wherein the 5-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl), wherein the 6-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(7-membered heteroaryl), wherein the 7-membered heteroaryl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl or C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl), wherein the C3-C8 cycloalkyl or 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl), wherein the 4- to 7-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5- to 6-membered heterocyclyl), wherein the 5- to 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl), wherein the 5-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl), wherein the 6-membered heterocyclyl is unsubstituted or substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) or (CRcRd)n-(5- to 10-membered heteroaryl) wherein the C6-C10 aryl or 5- to 10-membered heteroaryl is unsubstituted. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) or (CRcRd)n-(5- to 10-membered heteroaryl) wherein the C6-C10 aryl or 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) or (CRcRd)n-(5- to 10-membered heteroaryl) wherein the C6-C10 aryl or 5- to 10-membered heteroaryl is unsubstituted and further wherein n is 0. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) or (CRcRd)n-(5- to 10-membered heteroaryl) wherein the C6-C10 aryl or 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 0.
In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) or (CRcRd)n-(5- to 10-membered heteroaryl) wherein the C6-C10 aryl or 5- to 10-membered heteroaryl is unsubstituted and further wherein n is 1. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) or (CRcRd)n-(5- to 10-membered heteroaryl) wherein the C6-C10 aryl or 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 1.
In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) wherein the C6-C10 aryl is unsubstituted. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) wherein the C6-C10 aryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) wherein the C6-C10 aryl is unsubstituted and further wherein n is 0. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) wherein the C6-C10 aryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 0.
In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) wherein the C6-C10 aryl is unsubstituted and further wherein n is 1. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) wherein the C6-C10 aryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 1.
In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 10-membered heteroaryl) wherein the 5- to 10-membered heteroaryl is unsubstituted. In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 10-membered heteroaryl) wherein the 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 10-membered heteroaryl) wherein the 5- to 10-membered heteroaryl is unsubstituted and further wherein n is 0. In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 10-membered heteroaryl) wherein the 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 0.
In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 10-membered heteroaryl) wherein the 5- to 10-membered heteroaryl is unsubstituted and further wherein n is 1. In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 10-membered heteroaryl) wherein the 5- to 10-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 1.
In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(5- to 7-membered heteroaryl) wherein the phenyl or 5- to 7-membered heteroaryl is unsubstituted. In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(5- to 7-membered heteroaryl) wherein the phenyl or 5- to 7-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(5- to 7-membered heteroaryl) wherein the phenyl or 5- to 7-membered heteroaryl is unsubstituted and further wherein n is 0. In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(5- to 7-membered heteroaryl) wherein the phenyl or 5- to 7-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 0.
In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(5- to 7-membered heteroaryl) wherein the phenyl or 5- to 7-membered heteroaryl is unsubstituted and further wherein n is 1. In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(5- to 7-membered heteroaryl) wherein the phenyl or 5- to 7-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 1.
In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(6-membered heteroaryl) wherein the phenyl or 6-membered heteroaryl is unsubstituted. In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(6-membered heteroaryl) wherein the phenyl or 6-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(6-membered heteroaryl) wherein the phenyl or 6-membered heteroaryl is unsubstituted and further wherein n is 0. In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(6-membered heteroaryl) wherein the phenyl or 6-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 0.
In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(6-membered heteroaryl) wherein the phenyl or 6-membered heteroaryl is unsubstituted and further wherein n is 1. In another embodiment of Formula (I), R1 is (CRcRd)n-(phenyl) or (CRcRd)n-(6-membered heteroaryl) wherein the phenyl or 6-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 1.
In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl) wherein the 6-membered heteroaryl is unsubstituted. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl) wherein the 6-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of Formula (I), R1 is pyridazinyl. In another embodiment of Formula (I), R1 is 3-pyridazinyl.
In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl) wherein the 6-membered heteroaryl is unsubstituted and further wherein n is 0. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl) wherein the 6-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 0.
In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl) wherein the 6-membered heteroaryl is unsubstituted and further wherein n is 1. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl) wherein the 6-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 1.
In another embodiment of Formula (I), R1 is (CRcRd)n-(5-membered heteroaryl) wherein the 5-membered heteroaryl is unsubstituted. In another embodiment of Formula (I), R1 is (CRcRd)n-(5-membered heteroaryl) wherein the 5-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium.
In another embodiment of Formula (I), R1 is (CRcRd)n-(5-membered heteroaryl) wherein the 5-membered heteroaryl is unsubstituted and further wherein n is 0. In another embodiment of Formula (I), R1 is (CRcRd)n-(5-membered heteroaryl) wherein the 5-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 0.
In another embodiment of Formula (I), R1 is (CRcRd)n-(5-membered heteroaryl) wherein the 5-membered heteroaryl is unsubstituted and further wherein n is 1. In another embodiment of Formula (I), R1 is (CRcRd)n-(5-membered heteroaryl) wherein the 5-membered heteroaryl is substituted with one or more halogen, hydroxyl, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium and further wherein n is 1.
In another embodiment of Formula (I), each of R2, R3, R4, R5, R6, R7, and R8 is, independently, H, halogen, unsubstituted C1-C3 alkyl, or C1-C3 alkyl substituted with one or more halogen or deuterium. In another embodiment of Formula (I), each of R2, R3, R4, R5, R6, R7, and R8 is, independently, H, halogen, or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), each of R2, R3, R4, R5, R6, R7, and R8 is, independently, H or halogen. In another embodiment of Formula (I), each of R2, R3, R4, R5, R6, R7, and R8 is, independently, H or fluorine. In another embodiment of Formula (I), each of R2, R3, R4, R5, R6, R7, and R8 is, independently, H or C1-C3 alkyl. In another embodiment of Formula (I), each of R2, R3, R4, R5, R6, R7, and R8 is H.
In another embodiment of Formula (I), R3 and R6, together, form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted with one or more halogen. In another embodiment of Formula (I), R3 and R6, together, form an unsubstituted C2 alkylene or a C2 alkylene substituted with one or more halogen. In another embodiment of Formula (I), R3 and R6, together, form an azabicyclo[3.2.1]octanyl bridged bicyclic heterocyclyl.
In another embodiment of Formula (I), R4 and R5, together, form an unsubstituted C1-C3 alkylene or a C1-C3 alkylene substituted with one or more halogen. In another embodiment of Formula (I), R4 and R5, together, form an unsubstituted C2 alkylene or a C2 alkylene substituted with one or more halogen. In another embodiment of Formula (I), R4 and R5, together, form an azabicyclo[3.2.1]octanyl bridged bicyclic heterocyclyl.
In another embodiment of Formula (I), R1 is C(═O)—C1-C4 alkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—C1-C4 alkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—C1-C4 alkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—C1-C4 alkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—C1-C4 alkoxyl and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—C1-C4 alkoxyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—C1-C4 alkoxyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—C1-C4 alkoxyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd))n-(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6-C10 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n—(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5- to 7-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(5-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—(CRcRd)n-(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl, n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n—C3-C8 cycloalkyl, n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(4- to 7-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(5-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is C(═O)—O—(CRcRd)n-(6-membered heterocyclyl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 10-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 10-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 10-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 10-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CRcRd)n-(5- to 7-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CRcRd)n-(6-membered heteroaryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6-C10 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl) and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl), n is 0, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or unsubstituted C1-C3 alkyl. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or halogen. In another embodiment of Formula (I), R1 is (CRcRd)n—(C6 aryl), n is 1 or 2, and each of R2, R3, R4, R5, R6, R7, and R8 is H or fluorine.
Each of the embodiments described herein with respect to compounds of Formula I also applies to compounds of Formula I-A.
Certain embodiments of compounds of Formula I-A, or I, or pharmaceutically acceptable salts thereof, are shown below in Table 1. Compounds of Formula I-A, or I, or pharmaceutically acceptable salts thereof, and compounds of Table 1, or pharmaceutically acceptable salts thereof, collectively or individually are sometimes referred to herein as “compounds of the invention” or “compounds provided herein”.
The disclosed compounds possess one or more stereocenters, and each stereocenter may exist independently in either the R or S configuration. In one embodiment, compounds described herein are present in optically active or racemic forms. It is to be understood that the compounds described herein encompass racemic, optically-active, regioisomeric and stereoisomeric forms, or combinations thereof that possess the therapeutically useful properties described herein.
Preparation of optically active forms is achieved in any suitable manner, including by way of non-limiting example, by resolution of the racemic form with recrystallization techniques, synthesis from optically-active starting materials, chiral synthesis, or chromatographic separation using a chiral stationary phase. In one embodiment, a mixture of two or more isomers is utilized as the disclosed compound described herein. In another embodiment, a pure isomer is utilized as the disclosed compound described herein. In another embodiment, compounds described herein contain one or more chiral centers. These compounds are prepared by any means, including stereoselective synthesis, enantioselective synthesis or separation of a mixture of enantiomers or diastereomers. Resolution of compounds and isomers thereof is achieved by any means including, by way of non-limiting example, chemical processes, enzymatic processes, fractional crystallization, distillation, and chromatography.
In one embodiment, the disclosed compounds may exist as tautomers. All tautomers are included within the scope of the compounds presented herein.
Compounds described herein also include isotopically-labeled compounds wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds described herein include and are not limited to 2H 3H, 11C, 13C, 14C, 36Cl, 18F, 123I, 125I, 13N, 15N, 15O, 17O 18O, 32P, and 35S. In one embodiment, isotopically-labeled compounds are useful in drug or substrate tissue distribution studies. In another embodiment, substitution with heavier isotopes such as deuterium affords greater metabolic stability (for example, increased in vivo half-life or reduced dosage requirements). In another embodiment, the compounds described herein include a 2H (i.e., deuterium) isotope.
In yet another embodiment, substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, is useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds are prepared by any suitable method or by processes using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
The specific compounds described herein, and other compounds encompassed by one or more of the Formulas described herein having different substituents are synthesized using techniques and materials described herein and as described, for example, in Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4th Ed., (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4th Ed., Vols. A and B (Plenum 2000, 2001), and Green and Wuts, Protective Groups in Organic Synthesis 3rd Ed., (Wiley 1999) (all of which are incorporated by reference for such disclosure). General methods for the preparation of compounds as described herein are modified by the use of appropriate reagents and conditions, for the introduction of the various moieties found in the Formulas as provided herein.
Compounds described herein are synthesized using any suitable procedures starting from compounds that are available from commercial sources or are prepared using procedures described herein.
The compounds of the invention can be used in a method of treating a disease or condition in a subject, said method comprising administering to the subject a compound of the invention, or a pharmaceutical composition comprising a compound of the invention. In one embodiment of the methods described herein, the subject is human. In one aspect, the compounds provided herein are useful in treatment of a disease or condition by acting as an agonist of the orexin-2 receptor.
The compounds of the invention can be used to treat a disease or condition selected from the group consisting of narcolepsy, cataplexy, or hypersomnia in a subject in need thereof.
In one embodiment, the compounds of the invention can be used to treat narcolepsy in a subject. In one embodiment, the compounds of the invention can be used to treat cataplexy in a subject. In one embodiment, the compounds of the invention can be used to treat hypersomnia in a subject.
Orexin-2 receptors are important in a wide range of biological functions. This suggests that orexin-2 receptors play a role in diverse disease processes in humans or other species. The compound of the present invention is useful for treating, preventing, or ameliorating the risk of one or more of the following symptoms or diseases of various neurological and psychiatric diseases associated with alterations in sleep/wake function. That is, narcolepsy, narcolepsy with cataplexy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome, hypersomnolence syndrome characterized by hypersomnia (e.g., in subjects with Kleine Levin syndrome, major depression with hypersomnia, Lewy body dementia, Parkinson's disease, progressive supranuclear paralysis, Prader-Willi syndrome, Mobius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, brain contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, multiple systems atrophy, acute disseminated encephalomyelitis, Guillain-Barre syndrome, Rasmussen's encephalitis, Wernicke's encephalitis, limbic encephalitis, or Hashimoto's encephalopathy), coma, loss of consciousness, obesity (e.g., malignant mastocytosis, exogenous obesity, hyperinsulinar obesity, hyperplasmic obesity, hypop hyseal adiposity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, alimentary obesity, hypogonadal obesity, systemic mastocytosis, simple obesity, or central obesity), insulin resistance syndrome, Alzheimer's disease, disturbance of consciousness such as coma and the like, side effects and complications due to anesthesia, sleep disturbance, excessive daytime sleepiness, sleep problem, insomnia, intermittent sleep, nocturnal myoclonus, REM sleep interruption, jet lag, jet lag syndrome, sleep disorder of alternating worker, sleep disorder, night terror, depression, major depression, sleepwalking disease, enuresis, sleep disorder, Alzheimer's dusk, sundowning, diseases associated with circadian rhythm, fibromyalgia, condition arising from decline in the quality of sleep, overeating, obsessive compulsive eating disorder, obesity-related disease, hypertension, diabetes, elevated plasma insulin concentration and insulin resistance, hyperlipidemia, hyperlipemia, endometrial cancer, breast cancer, prostate cancer, colorectal cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, cardiac disease, abnormal heartbeat, arrhythmia, myocardial infarction, congestive cardiac failure, cardiac failure, coronary heart disease, cardiovascular disorder, polycysticovarian disease, craniopharingioma, Prader-Willi syndrome, Froelich's syndrome, growth hormone deficient, normal mutant short stature, Turner's syndrome, children suffering from acute lymphoblastic leukemia, syndrome X, reproductive hormone abnormality, declining fertility, infertility, male gonadal function decline, sexual and reproductive dysfunction such as female male hirsutism, fetal defects associated with pregnant women obesity, gastrointestinal motility disorders such as obesity-related gastroesophageal reflux, obesity hypoventilation syndrome (Pickwick syndrome), respiratory diseases such as dyspnea, inflammation such as systemic inflammation of the vascular system, arteriosclerosis, hypercholesterolemia, hyperuricemia, lower back pain, gall bladder disease, gout, kidney cancer, risk of secondary outcomes of obesity, such as lowering the risk of left ventricular hypertrophy, migraine pain, headache, neuropathic pain, Parkinson's disease, psychosis, autoimmune encephalitis, cancer related fatigue (such as excessive daytime sleepiness or fatigue associated with cancer and/or chemotherapy), cancer related nausea and vomiting, corticobasal degeneration, Huntington's disease, neuromyelitis optica, nociception, progressive supranuclear palsy, schizophrenia, systemic lupus erythematosus, traumatic brain injury, facial flushing, night sweats, diseases of the genital/urinary system, diseases related to sexual function or fertility, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive disorder, panic attack, panic disorder, post-traumatic stress disorder (PTSD), separation anxiety disorder, social phobia, anxiety disorder, acute neurological and psychiatric disorders such as cardiac bypass surgery and post-transplant cerebral deficit, stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic nerve injury, Huntington's chorea, amyotrophic lateral sclerosis, eye damage, retinopathy, cognitive impairment, muscle spasm, tremor, epilepsy, disorders associated with muscle spasticity, delirium, amnestic disorder, age-related cognitive decline, schizoaffective disorder, delusional disorder, drug addiction, dyskinesia, chronic fatigue syndrome, fatigue, medication-induced Parkinsonism syndrome, Jill-do La Tourette's syndrome, chorea, myoclonus, tic, restless legs syndrome, dystonia, dyskinesia, attention deficit hyperactivity disorder (ADHD), behavior disorder, urinary incontinence, withdrawal symptoms, trigeminal neuralgia, hearing loss, tinnitus, nerve damage, retinopathy, macular degeneration, vomiting, cerebral edema, pain, bone pain, arthralgia, toothache, cataplexy, and traumatic brain injury (TBI).
Particularly, the compound of the present invention is useful as a therapeutic or prophylactic drug for narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome, hypersomnolence syndrome characterized by hypersomnia (e.g., in Parkinson's disease, Guillain-Barre syndrome or Kleine Levin syndrome), Alzheimer's disease, obesity, insulin resistance syndrome, cardiac failure, diseases related to bone loss, sepsis, disturbance of consciousness such as coma and the like, side effects and complications due to anesthesia, and the like, or anesthetic antagonist.
In one embodiment, the compound of the present invention has orexin-2 receptor agonist activity and is useful as a prophylactic or therapeutic agent for narcolepsy.
In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for narcolepsy type-1. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for narcolepsy type-2. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for narcolepsy and excessive daytime sleepiness. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for narcolepsy, cataplexy, and excessive daytime sleepiness. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for narcolepsy and cataplexy. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for excessive daytime sleepiness. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for idiopathic hypersomnia. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for obstructive sleep apnea.
In another embodiment, the compound of the present invention has orexin-2 receptor agonist activity and is useful as a prophylactic or therapeutic agent for hypersomnia in Parkinson's disease.
In another embodiment, the compound of the present invention has orexin-2 receptor agonist activity and is useful as a prophylactic or therapeutic agent for hypersomnia. In another embodiment, the compound of the present invention has orexin-2 receptor agonist activity and is useful as a prophylactic or therapeutic agent for excessive daytime sleepiness associated with Parkinson's disease.
In another embodiment, the compound of the present invention has orexin-2 receptor agonist activity and is useful as a prophylactic or therapeutic agent for excessive daytime sleepiness or fatigue associated with cancer and/or chemotherapy.
In another embodiment, the present invention provides a method of treating narcolepsy in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a method of treating narcolepsy type-1 in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a method of treating narcolepsy type-2 in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a method of treating narcolepsy and excessive daytime sleepiness in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a method of treating narcolepsy, cataplexy, and excessive daytime sleepiness in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a method of treating narcolepsy and cataplexy in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a method of treating excessive daytime sleepiness in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a method of treating idiopathic hypersomnia in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a method of treating excessive daytime sleepiness and idiopathic hypersomnia in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a method of treating obstructive sleep apnea in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a method of treating excessive daytime sleepiness and obstructive sleep apnea in a subject in need thereof comprising administering to the subject a compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof.
In any of the methods as described herein, the subject is administered a compound of Formula I.
Each of the embodiments described herein with respect to the use of compounds of Formula I also applies to compounds of Formula I-A.
In any of the compositions or methods as described herein, the compound of Formula I-A, or I, or a pharmaceutically acceptable salt thereof, is present and/or administered in a therapeutically effective amount.
In another aspect, provided herein is a pharmaceutical composition comprising at least one compound of the invention, together with a pharmaceutically acceptable carrier.
Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
In particular, the selected dosage level will depend upon a variety of factors including the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well, known in the medical arts.
A medical doctor, e.g., physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could begin administration of the pharmaceutical composition to dose the disclosed compound at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
In particular embodiments, it is especially advantageous to formulate the compound in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the patients to be treated; each unit containing a predetermined quantity of the disclosed compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle. The dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the disclosed compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding/formulating such a disclosed compound for the treatment of narcolepsy or cataplexy in a patient.
In one embodiment, the compounds of the invention are formulated using one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions of the invention comprise a therapeutically effective amount of a disclosed compound and a pharmaceutically acceptable carrier.
In some embodiments, the dose of a disclosed compound is from about 1 mg to about 1,000 mg. In some embodiments, a dose of a disclosed compound used in compositions described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 20 mg, or less than about 10 mg. For example, a dose is about 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, 200 mg, 220 mg, 240, 260 mg, 280 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, or about 600 mg.
Routes of administration of any of the compositions of the invention include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual or topical. The compounds for use in the invention may be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration. In one embodiment, the preferred route of administration is oral.
Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions that would be useful in the present invention are not limited to the particular formulations and compositions that are described herein.
For oral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, or capsules, caplets and gelcaps. The compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutically excipients that are suitable for the manufacture of tablets. Such excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate. The tablets may be uncoated or they may be coated by known techniques for elegance or to delay the release of the active ingredients. Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert diluent.
For parenteral administration, the disclosed compounds may be formulated for injection or infusion, for example, intravenous, intramuscular or subcutaneous injection or infusion, or for administration in a bolus dose or continuous infusion. Suspensions, solutions or emulsions in an oily or aqueous vehicle, optionally containing other formulatory agents such as suspending, stabilizing or dispersing agents may be used.
Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents are considered to be within the scope of this invention and covered by the claims appended hereto. For example, it should be understood, that modifications in reaction conditions, including but not limited to reaction times, reaction size/volume, and experimental reagents, such as solvents, catalysts, pressures, atmospheric conditions, e.g., nitrogen atmosphere, and reducing/oxidizing agents, with art-recognized alternatives and using no more than routine experimentation, are within the scope of the present application.
It is to be understood that wherever values and ranges are provided herein, all values and ranges encompassed by these values and ranges, are meant to be encompassed within the scope of the present invention. Moreover, all values that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the present application.
The following examples further illustrate aspects of the present invention. However, they are in no way a limitation of the teachings or disclosure of the present invention as set forth herein.
The invention is further illustrated by the following examples, which should not be construed as further limiting. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of organic synthesis, cell biology, cell culture, molecular biology, transgenic biology, microbiology and immunology, which are within the skill of the art.
Synthesis procedures for preparation of the compounds of the invention are readily available to the ordinary skilled artisan. Unless otherwise indicated, starting materials were generally obtained from commercial sources. Synthetic procedures for other related compounds can be found, for example, in U.S. application Ser. No. 17/556,295, filed Dec. 20, 2021 and in PCT Application No.: PCT/US21/64484, filed Dec. 21, 2021; both of which are expressly incorporated by reference herein.
The following abbreviations may be used in the synthetic examples below:
To a solution of 4-hydroxycyclohexan-1-one (10 g, 1 eq, 88 mmol) and DMAP (1.1 g, 0.1 eq, 8.8 mmol) in DCM (200 mL) was added benzoyl chloride (15 g, 1.2 eq, 0.11 mol) and triethylamine (13 g, 18 mL, 1.5 eq, 0.13 mol) at 0 degrees C. The resulting mixture was stirred at 25 degrees C. for 3 hours. Desired product could be detected by LCMS. The resulting mixture was diluted with water and extracted with DCM (3×100 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude was purified by flash chromatography over silica gel and eluted with EtOAc/PE (20% gradient) to afford 4-oxocyclohexyl benzoate (7.4 g, 34 mmol, 39%) as an oil. 1H NMR (400 MHz, Methanol-d4) δ8.14-7.97 (m, 2H), 7.59 (dt, 1H), 7.47 (q, 2H), 5.39 (p, 1H), 2.62 (dt, 1H), 2.42 (dt, 1H), 2.19 (q, 3H), 2.01-1.69 (m, 3H).
To a stirred solution of triphenyl phosphite (8 g, 1.1 eq, 0.03 mol) in DCM (50 mL) was added Br2 (4 g, 1 mL, 1.2 eq, 0.03 mol) at −60 degrees C. The mixture was stirred for 30 minutes at 25 degrees C. 4-oxocyclohexyl benzoate (5 g, 1 eq, 0.02 mol) and triethylamine (3 g, 1.3 eq, 0.03 mol) was added into the mixture at −60 degrees C. The resulting mixture was stirred for 16 hours at 25 degrees C. The resulting mixture was diluted with H2O (50 mL) and extracted with DCM (3×210 mL). The combined organic layers were washed with brine (3×100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude was purified by flash chromatography over silica gel and eluted with EtOAc/PE (0-25% gradient) to afford 4-bromocyclohex-3-en-1-yl benzoate (5 g, 0.02 mol, 80%) as a solid. 1H NMR (CDCl3, 400 MHz)δ2.00-2.17 (2H, m), 2.30-2.43 (1H, m), 2.50-2.59 (1H, m), 2.59-2.77 (2H, m), 5.34 (1H, dtd), 6.01 (1H, tt), 7.42-7.51 (2H, m), 7.54-7.63 (1H, m), 8.02-8.09 (2H, m).
To a stirred solution of 4-bromocyclohex-3-en-1-yl benzoate (15 g, 1 eq, 53 mmol) in MeOH (150 mL) was added sodium methanolate (3.2 g, 1.1 eq, 59 mmol) in portions at 25 degrees C. under N2 atmosphere. The resulting mixture was stirred for 16 hours at 25 degrees C. Desired product could be detected by TLC. The resulting mixture was extracted with DCM (3×80 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude was purified by flash chromatography over silica gel and eluted with EtOAc/PE (20% gradient) to afford 4-bromocyclohex-3-en-1-ol (7 g, 0.04 mol, 70%) as an oil. 1H NMR (400 MHz, Methanol-d4) δ5.92 (ddt, 1H), 3.93 (dddd, 1H), 2.72-2.28 (m, 3H), 2.16-1.69 (m, 4H).
To a stirred solution of 4-bromocyclohex-3-en-1-ol (6.15 g, 1 eq, 34.7 mmol) and TMS-Cl (15.1 g, 17.6 mL, 4 eq, 139 mmol) in TMS-Cl (17 mL) was added paraformaldehyde (1.56 g, 1.5 eq, 52.1 mmol) in portions at 25 degrees C. The resulting mixture was stirred for 16 hours at 25 degrees C. The resulting mixture was filtered, the filter cake was washed with TMS-Cl (3×10 mL). The filtrate was concentrated under reduced pressure. The crude product was used in the next step directly without further purification. 1H NMR (400 MHz, CDCl3, 22° C.) δ1.8-2.05 (m, 2H), 2.13-2.44 (m, 2H), 2.45-2.66 (m, 2H), 4.12 (dddd, 1H), 5.58 (s, 1H), 5.94 (tt, 1H).
To a stirred solution of diethylamine (0.9 g, 1 mL, 1.2 eq, 0.01 mol) in tetrahydrofuran (24 mL) was added n-butyllithium (0.8 g, 1.2 eq, 0.01 mol) in portions at −78 degrees C. under N2 atmosphere. The resulting mixture was stirred for 30 minutes at −78 degrees C. To the above reaction mixture was added a solution of 1-benzyl-N-(1-phenylethyl)piperidin-4-imine (3 g, 1 eq, 0.01 mol) in tetrahydrofuran (15 mL) dropwise. The reaction mixture was stirred at −78 degrees C. for an additional 1 hour. To the above reaction mixture was added a solution of 1-bromo-4-(chloromethoxy)cyclohex-1-ene (3 g, 1.2 eq, 0.01 mol) in tetrahydrofuran (15 mL) dropwise. The reaction mixture was stirred at −78 degrees C. for an additional 1 hour. The reaction was quenched by the addition of saturated ammonium chloride solution and stirred for 1 hour. The resulting mixture was extracted with DCM (3×80 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse flash chromatography (column, C18 silica gel; mobile phase, MeCN in NH4HCO3 water, 0% to 100% gradient in 25 min) to afford 1-benzyl-3-(((4-bromocyclohex-3-en-1-yl)oxy)methyl)piperidin-4-one (1.8 g, 4.8 mmol, 50%) as an oil.
LCMS: m/z (ES+), [M+H]+=378.1.
To a stirred solution of 1-benzyl-3-(((4-bromocyclohex-3-en-1-yl)oxy)methyl)piperidin-4-one (2 g, 1 eq, 5 mmol) in MeOH (100 mL) was added ammonium formate (5 g, 15 eq, 0.08 mol) followed by sodium cyanoborohydride (2 g, 6 eq, 0.03 mol) in portions over 15 minutes at 25 degrees C. The resulting mixture was stirred for 3 hours at 25 degrees C. The reaction was quenched by the addition of ammonium chloride saturated solution and stirred for 15 minutes. The resulting mixture was extracted with DCM (3×80 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse flash chromatography (column, C18 silica gel; mobile phase, MeCN in NH4HCO3 water, 0% to 100% gradient in 20 min) to afford 1-benzyl-3-(((4-bromocyclohex-3-en-1-yl)oxy)methyl)piperidin-4-amine (1.5 g, 4.0 mmol, 70%) as an oil.
LCMS: m/z (ES+), [M+H]+=379.25.
To a stirred solution of 1-benzyl-3-(((4-bromocyclohex-3-en-1-yl)oxy)methyl)piperidin-4-amine (5 g, 1 eq, 0.01 mol) and Et3N (7 g, 9 mL, 5 eq, 0.07 mol) in DCM (250 mL) was added trifluoromethanesulfonic anhydride (4 g, 1.2 eq, 0.02 mol) in portions at −50 degrees C. under N2 atmosphere. The resulting mixture was stirred for 15 minutes at −50 degrees C. The reaction was quenched by the addition of saturated ammonium bicarbonate solution and stirred for 3 minutes. The resulting mixture was extracted with DCM (3×50 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse flash chromatography (column, C18 silica gel; mobile phase, MeCN in NH4HCO3 water, 0% to 100%) to afford desired product (5 g, 0.01 mol, 70%) as an oil.
The mixture product (13.25 g, combined from multiple batches) was purified by achiral SFC (column: DAICEL DCpak P4VP, 5*25 cm, 5 m; Mobile Phase A: CO2, Mobile Phase B: ACN:MEOH=4:1 (0.1% 2M NH3-MEOH); Flow rate: 200 mL/min; Gradient: isocratic 30% B; Column Temperature (° C.): 35; Back Pressure (bar): 100; Wave Length: 220 nm) to afford the product (3.18 g, 4.8 mmol, 24%, 97% purity) as an oil.
LCMS: m/z (ES+), [M+H]+=513.0.
(300 MHz, Chloroform-d) δ 7.53-7.02 (m, 6H), 5.89 (t, J=4.4 Hz, 1H), 4.21 (t, J=9.9 Hz, 1H), 3.79-3.22 (m, 5H), 2.80 (d, J=11.7 Hz, 1H), 2.67-2.30 (m, 4H), 2.29-2.02 (m, 4H), 2.02-1.72 (m, 4H).
To a solution of 1-benzyl-3-(((4-bromocyclohex-3-en-1-yl)oxy)methyl)piperidin-4-amine (13.00 g, 1 eq, 34.27 mmol) in DCM (150 mL) was added TEA (10.40 g, 14.3 mL, 3 eq, 102.8 mmol). Then to the mixture was added methanesulfonic anhydride (7.163 g, 1.2 eq, 41.12 mmol) at 0 degrees C. The resulting mixture was stirred for 1.5 hours at 25 degrees C. The reaction was monitored by LCMS. The reaction was quenched by saturated NaHCO3 solution. The resulting mixture was extracted with DCM (3×200 mL). The combined organic layers were concentrated under reduced pressure. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 10% to 80% gradient in 40 min, hold 15 minutes at 60%) to afford the crude product (13.00 g, 28.42 mmol, 82.93%) as an oil.
The product mixture (62 g, combined from multiple batches) was purified by achiral SFC (column: DAICEL Dcpak P4VP, 4.6*50 mm, 3 um; Mobile Phase B: ACN:MeOH=80:20 (1% 2M NH3-MeOH)) to afford the product (15 g, 33 mmol, 24.2%).
(400 MHz, Chloroform-d) δ 7.38-7.24 (m, 5H), 5.92 (tq, J=3.5, 1.8 Hz, 1H), 5.78 (d, J=25.8 Hz, 1H), 3.99 (d, J=17.4 Hz, 1H), 3.70-3.58 (m, 2H), 3.54 (td, J=11.2, 10.2, 5.5 Hz, 2H), 3.42 (d, J=13.2 Hz, 1H), 2.97 (s, 3H), 2.69 (s, 1H), 2.63-2.43 (m, 3H), 2.43-2.25 (m, 3H), 2.25-2.03 (m, 2H), 2.03-1.76 (m, 4H).
To a solution of 1-benzyl-3-(((4-bromocyclohex-3-en-1-yl)oxy)methyl)piperidin-4-amine (8.02 g, 1 eq, 21.1 mmol) and N-ethyl-N-isopropylpropan-2-amine (8.20 g, 3 eq, 63.4 mmol) in DCM (80 mL) was added di-tert-butyl dicarbonate (4.61 g, 1 eq, 21.1 mmol). The resulting mixture was stirred for 2 hours at 25 degrees C. The crude was purified by flash chromatography over silica gel and eluted with PE/EtOAc (0-12% gradient) to afford 4.5 g crude product as an oil. The above mixture was purified by achiral SFC rep-achiral-SFC (column: Viridis BEH 2-EP, 100*4.6 mmm, Sum; Mobile Phase B: MeOH (1% 2M NH3-MeOH); Flow rate: 4 mL/min; Gradient: isocratic 5% B) to afford the product (1.79 g, 3.73 mmol, 17.9%) as an oil.
LCMS: m/z (ES+), [M+H]+=481.1.
1H NMR (400 MHz, Chloroform-d) δ 7.33 (s, 5H), 5.91 (s, 1H), 5.68 (s, 1H), 3.83 (d, J=47.2 Hz, 2H), 3.64-3.33 (m, 3H), 2.76-2.23 (m, 6H), 2.14 (d, J=17.9 Hz, 2H), 2.03 (s, 1H), 1.97-1.73 (m, 3H), 1.46 (s, 9H).
To a solution of vinyl bromide (1.79 g, 1 eq, 3.73 mmol) and (1-methyl-1H-indazol-5-yl)boronic acid (723 mg, 1.1 eq, 4.11 mmol) in 1,4-dioxane (30 mL) and water (6.0 mL) were added Na2CO3 (1.19 g, 3 eq, 11.2 mmol) and PdCl2(dppf)·CH2Cl2 (305 mg, 0.1 eq, 373 μmol). After stirring for 22 hours at 80 degrees C. under a nitrogen atmosphere, the resulting mixture was diluted with H2O (100 mL) and extracted with EtOAc (3×200 mL). The combined organic layers were washed with brine (3×200 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC with EtOAc/PE (2/1) to afford the product (1.68 g, 3.17 mmol, 84.8%) as an oil.
LCMS: m/z (ES+), [M+H]+=531.5.
1H NMR (400 MHz, Chloroform-d) δ 7.96 (dd, J=2.0, 1.0 Hz, 1H), 7.77-7.64 (m, 1H), 7.51 (dd, J=8.8, 1.7 Hz, 1H), 7.41-7.25 (m, 7H), 6.01 (s, 1H), 4.09 (s, 3H), 3.94 (d, J=25.8 Hz, 1H), 3.80 (s, 1H), 3.51 (s, 6H), 2.72-2.50 (m, 4H), 2.28 (d, J=9.2 Hz, 2H), 2.07 (s, 1H), 1.86 (s, 2H), 1.65 (s, 2H), 1.51-1.22 (m, 9H), 1.05 (s, 1H).
To a solution of tert-butyl olefin (1.65 g, 1 eq, 3.11 mmol) and 1,1,2-trichloroethane (498 mg, 347 μL, 1.2 eq, 3.73 mmol) in i-PrOH (40 mL) was added Pd/C (1.65 g, 10% Wt, 0.5 eq, 1.55 mmol) and palladium(2+) dihydroxide (2.18 g, 10% wt, 0.5 eq, 1.55 mmol) at nitrogen atmosphere. The resulting mixture was hydrogenated at room temperature for 4 hours under hydrogen atmosphere using a hydrogen balloon. Crude reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford the crude product. The crude product was used in the next step directly without further purification.
LCMS: m/z (ES+), [M+H]+=443.2.
To a solution of the amine (100.0 mg, 1 eq, 225.9 μmol) and 3-bromopyridazine (71.84 mg, 2 eq, 451.9 μmol) in DMSO (5 mL) was added Cs2CO3 (147.2 mg, 2 eq, 451.9 μmol) and PEPPSI-Pd (19.00 mg, 0.1 eq, 22.59 μmol). The resulting mixture was stirred for 4 hours at 120 degrees C. under a nitrogen atmosphere. A total of 12 reactions were done in parallel. The resulting mixture was extracted with ethyl acetate (3×200 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (MeOH/DCM=1/15) to afford the product (620 mg, 1.19 mmol, 47.7%) as an oil.
LCMS: m/z (ES+), [M+H]+=521.2.
To a stirred solution of Boc protected amine (200 mg, 1 eq, 384.1 μmol) in 1,4-dioxane (6 mL) was added HCl (70 mg, 480.1 μL, 4 molar, 5 eq, 1.921 mmol) at room temperature. The mixture solution was stirred for 1 hour at room temperature. The resulting solution was evaporated under reduced pressure to afford the product amine (150.0 mg, 356.7 μmol, 92.85%) as a solid as HCl salt. The crude product was used in the next step directly without further purification.
LCMS: m/z (ES+), [M+H]+=421.30.
To a solution of vinyl bromide (1.50 g, 1 eq, 2.93 mmol) and Pd(Ph3P)4 (339 mg, 0.1 eq, 293 μmol) in 1,4-dioxane (20 mL) and water (4.0 mL) were added Cs2CO3 (2.87 g, 3 eq, 8.80 mmol) and (1-methyl-1H-indazol-6-yl)boronic acid (671 mg, 1.3 eq, 3.81 mmol). After stirring for 3 hours at 80 degrees C. under a nitrogen atmosphere, the resulting mixture was diluted with H2O (20 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine (3×20 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC with EtOAc/PE (5% TEA) to afford the product (930 mg, 1.65 mmol, 56.4%) as a solid.
LCMS: m/z (ES+), [M+H]+=563.25.
To a solution of olefin (300 mg, 1 eq, 533 μmol) in i-PrOH (60 mL) was added Pd(OH)2 (37.4 mg, 0.5 eq, 267 μmol), Pd/C (28.4 mg, 0.5 eq, 267 μmol) and 1,1,2-trichloroethane (142 mg, 2 eq, 1.07 mmol) at nitrogen atmosphere. The resulting mixture was hydrogenated at room temperature for 3 hours under hydrogen atmosphere using a hydrogen balloon. The resulting mixture was filtered through a celite pad and concentrated under reduced pressure to afford the crude product as an HCl salt. The crude was used to the next step directly.
LCMS: m/z (ES+), [M+H]+=475.10.
To the solution of vinyl bromide (2.00 g, 1 eq, 4.37 mmol) in 1,4-dioxane (20 mL) were added (1-methyl-1H-indazol-5-yl)boronic acid (846 mg, 1.1 eq, 4.81 mmol), K2CO3 (1.81 g, 3 eq, 13.1 mmol), water (4.0 mL) and Pd(PPh3)4 (505 mg, 0.1 eq, 437 μmol) at room temperature. The mixture solution was stirred for 2 hours at 80 degrees C. under N2 atmosphere. The reaction was monitored by LCMS. The mixture was diluted with water and extracted with EA. The combined organic phase was concentrated under reduced pressure. The residue was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 5% to 65% gradient in 30 min; detector, UV 254 nm) to afford the desired product (1.70 g, 3.34 mmol, 76.4%) as an oil.
LCMS: m/z (ES+), [M+H]+=509.3.
To the solution of olefin (1.70 g, 1 eq, 3.34 mmol) in i-PrOH (5 mL) were added 1,1,2-trichloroethane (892 mg, 621 μL, 2 eq, 6.68 mmol), Pd(OH)2 (1.41 g, 10% wt, 0.3 eq, 1.00 mmol) and Pd/C (1.07 g, 10% wt, 0.3 eq, 1.00 mmol) at room temperature. The mixture was stirred for 32 hours at 20 degrees C. under H2 atmosphere. The reaction was monitored by LCMS. The solution was filtered through a celite pad and concentrated under reduced pressure to afford the product (1.40 g, 3.06 mmol, 92%).
LCMS: m/z (ES+), [M+Na]+=421.25.
To a solution of vinyl bromide (2.00 g, 1 eq, 4.37 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.67 g, 1.5 eq, 6.56 mmol) and KOAc (858 mg, 2 eq, 8.74 mmol) in dioxane (20 mL) was added PdCl2(dppf)-CH2Cl2 adduct (179 mg, 0.05 eq, 219 μmol). The resulting mixture was stirred for 4 hours at 100 degrees C. under nitrogen atmosphere. The resulting mixture was filtered, the filtered cake was washed with EA (3×10 mL). The filtrate was concentrated under reduced pressure. The crude product (1.8 g) was used in the next step directly without further purification.
LCMS: m/z (ES+), [M+H]+=505.
To a solution of boronic ester (550 mg, 1 eq, 1.09 mmol) and 5-bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine (231 mg, 1 eq, 1.09 mmol) in 1,4-dioxane (8 mL) and H2O (0.2 ml) was added Na2CO3 (347 mg, 3 eq, 3.27 mmol) and PdCl2 (dppf)·CH2Cl2 adduct (44.5 mg, 0.05 eq, 54.5 μmol) under nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 80 degrees C. The resulting mixture was filtered, the filtered cake was washed with MeOH (3×10 mL). The filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water (NH4HCO3), mobile phase B: ACN, 55% to 65% gradient in 10 min; detector, UV 254 nm) to afford crude (220 mg) as a solid. The crude was purified by Prep-TLC (EA/PE=4/1.5% TEA) to afford the product (180 mg, 353 μmol, 32.4%) as a solid.
LCMS: m/z (ES+), [M+H]+=510.0.
To a solution of olefin (150 mg, 1 eq, 294 μmol) and Boc2O (128 mg, 135 μL, 2 eq, 589 μmol) in i-PrOH (18 mL) was added Pd/C (150 mg, 10% wt, 0.479 eq, 141 μmol) under nitrogen atmosphere. The resulting mixture was hydrogenated at room temperature for 30 hours under hydrogen atmosphere using a hydrogen balloon. Reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford the crude product. The crude product was used in the next step directly without further purification.
LCMS: m/z (ES+), [M+H]+=522.
A solution of N-Boc protected amine (150 mg, 1 eq, 288 μmol) and HCl in 1,4-dioxane (2 mL) was stirred for 1.5 hours at 25 degrees C. The resulting mixture was concentrated under reduced pressure to afford the crude product. The crude was lyophilized to afford the product amine as HCl salt (110 mg, 240 μmol, 83.5%) as a solid.
LCMS: m/z (ES+), [M+H]+=422.
To a solution of vinyl bromide (1.68 g, 1 eq, 3.29 mmol) and 7-fluoro-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (1 g, 1 eq, 4 mmol) and PdCl2(dppf)·CH2Cl2 adduct (240 mg, 0.1 eq, 329 μmol) and Na2CO3 (1.04 g, 3 eq, 9.86 mmol) in dioxane (10 mL) and water (2 mL). The resulting mixture was stirred for 4 hours at 80 degrees C. The resulting mixture was extracted with ethyl acetate/water (3×100 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure. The crude was purified by flash chromatography over silica gel eluted with EtOAc/PE (0-100% gradient) to afford product (3.17 g, 5.46 mmol, 60%).
LCMS: m/z (ES+), [M+H]+=581.45.
To a solution of the olefin (2.17 g, 1 eq, 3.74 mmol) was added Pd(OH)2 (2.10 g, 4 eq, 14.9 mmol) and 1,1,2-trichloroethane (499 mg, 347 μL, 1 eq, 3.74 mmol) and Pd/C (1.99 g, 5 eq, 18.7 mmol) in i-PrOH (10 mL). The resulting mixture was stirred for 3 hours at 25 degrees C. The resulting mixture was filtered, the filtered cake was washed with [isopropanol+hydrochloric acid (10%)](3×100 ML). The filtrate was concentrated under reduced pressure to afford the product (1.92 g, 2.7 mmol, 73%, 73% purity).
LCMS: m/z (ES+), [M+H]+=493.10.
To a test-tube fitted with an air-tight screw cap was added vinyl bromide (100 mg, 1 eq, 219 μmol), tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole-1-carboxylate (97.8 mg, 1.3 eq, 284 μmol), Na2CO3 (69.5 mg, 3 eq, 656 μmol), dioxane (2 mL) and H2O (0.7 mL) followed by PdCl2(dppf) (16.0 mg, 0.1 eq, 21.9 μmol). The resulting mixture was stirred at 80 degrees C. for 1 hour. The reaction mixture was extracted with DCM (3×100 mL) and water. The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and purified by thin layer chromatography (PE:EA=1:3) to afford the product (70 mg, 0.10 mmol, 47%, 87% purity) as a solid.
LCMS: m/z (ES+), [M+H]+=595.30.
1H NMR (400 MHz, Chloroform-d) δ 1.24-1.32 (m, 2H), 1.73 (s, 9H), 1.89 (s, 3H), 2.07 (s, 1H), 2.31 (s, 5H), 2.58 (s, 3H), 2.65 (s, 3H), 2.93 (d, 3H), 3.43 (s, 1H), 3.51 (s, 1H), 3.69 (s, 3H), 4.15 (q, 1H), 6.07 (s, 1H), 7.33 (s, 6H), 7.43 (dd, 1H), 7.72 (d, 1H), 8.05 (s, 1H), 8.41 (s, 1H).
To a test-tube fitted with an air-tight screw cap was added tert-butyl 5-(4-(((3R,4S)-1-benzyl-4-(methylsulfonamido)piperidin-3-yl)methoxy)cyclohex-1-en-1-yl)-1H-benzo[d]imidazole-1-carboxylate (150 mg, 1 eq, 252 μmol), H2 (5.09 mg, 10 eq, 2.52 mmol), i-PrOH (4 mL) and followed by Pd/C (8.05 mg, 0.3 eq, 75.7 μmol). The resulting mixture is stirred at 25 degrees C. for 12 hours. At which point LCMS analysis indicated completion of the reaction, then the reaction mixture was filtered through a pad of celite and rinsed thoroughly with methylene chloride. The filtrate was concentrated under reduced pressure and the crude material was purified by thin layer chromatography (PE:EA=1:2) to afford product amine (60 mg, 0.12 mmol, 47%) as a solid. LCMS: m/z (ES+), [M+H]+=507.25.
1H NMR (400 MHz, Chloroform-d) δ 0.04-0.13 (m, 1H), 0.09 (s, 12H), 1.22-1.33 (m, 5H), 1.30 (s, 1H), 1.39-1.53 (m, 1H), 1.72 (d, 11H), 1.79 (d, 1H), 1.90 (s, 1H), 1.94-2.14 (m, 2H), 2.22 (d, 2H), 2.63-2.74 (m, 1H), 2.83-3.15 (m, 2H), 3.01 (s, 2H), 3.59-3.74 (m, 2H), 3.78 (s, 1H), 3.93 (q, 1H), 6.06 (s, 1H), 6.19 (s, OH), 7.26-7.37 (m, 1H), 7.71 (dd, 1H), 7.86-7.93 (m, 1H), 8.35-8.43 (m, 1H).
To a stirred mixture of vinyl bromide (3.60 g, 1 eq, 7.87 mmol) and tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-1-carboxylate (2.84 g, 1.05 eq, 8.26 mmol) and Na2CO3 (139 mg, 3 eq, 1.31 mmol) in 1,4-dioxane (32 mL) and H2O (0.4 ml) was added PdCl2 (dppf) (576 mg, 0.1 eq, 787 μmol) under nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 80 degrees C. The resulting mixture was extracted with ethyl acetate (3×20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 90% to 100% gradient in 20 min; detector, UV 254 nm) to afford a mixture. The mixture was concentrated under reduced pressure to afford crude (4.3 g) as a solid. This material was repurified by flash chromatography over silica gel eluted with EtOAc/PE (100% gradient) to afford the product (2.56 g, 4.30 mmol, 54.7%) as a solid. LCMS: m/z (ES+), [M+H]+=595.
To a solution of tert-butyl olefin (1.500 g, 1 eq, 2.522 mmol) in i-PrOH (170 mL) was added Pd/C (1.5 g, 10% wt, 0.56 eq, 1.4 mmol) at nitrogen atmosphere. The resulting mixture was stirred at room temperature for 5 days under hydrogen atmosphere using a hydrogen balloon, filtered through a Celite pad and concentrated under reduced pressure to afford the crude product (1 g). LCMS: m/z (ES+), [M+H]+=507.
To a solution of vinyl bromide (250 mg, 1 eq, 489 μmol) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (143 mg, 1.2 eq, 587 μmol) in water (5 mL) 1,4-dioxane (20 mL) was added Na2CO3 (155 mg, 3 eq, 1.47 mmol) and PdCl2(dppf) (200 mg, 0.5 eq, 244 μmol). The resulting mixture was stirred for 8 hours at 80 degrees C. The resulting mixture was extracted with dichloromethane (3×20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (EA/PE=1/1) to afford the product (100 mg, 182 μmol, 37.3%) as a solid. LCMS: m/z (ES+), [M+H]+=549.20.
To a solution of the olefin (139 mg, 1 eq, 253 μmol) in i-PrOH (20 mL) was added Pd/C (135 mg, 5 eq, 1.27 mmol). The resulting mixture was stirred for 8 hours at 25 degrees C. under hydrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture filtered, the filtrate was concentrated under reduced pressure to the product amine (68 mg, 148 μmol, 58.7%) as a solid.
LCMS: m/z (ES+), [M+H]+=461.35.
To a stirred mixture of vinyl bromide (300 mg, 1 eq, 656 μmol) and 3-hydroxy-2,3-dimethylbutan-2-yl hydrogen (1-methyl-1H-benzo[d]imidazol-6-yl)boronate (217 mg, 1.2 eq, 787 μmol) in 1,4-dioxane (15 mL) and water (0.8 mL) were added Cs2CO3 (641 mg, 3 eq, 1.97 mmol) and Pd(Ph3P)4 (152 mg, 0.2 eq, 131 μmol) at room temperature under nitrogen atmosphere. The final reaction mixture was stirred for 3 hours at 80 degrees C. The resulting mixture was diluted with H2O (50 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine (1×50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: 8 mmol NH4HCO3, mobile phase B: ACN, 10% to 90% gradient in 45 min) to afford the product (180 mg, 354 μmol, 54.0%) as an oil.
LCMS: m/z (ES+), [M+H]+=509.
To a solution of olefin (180 mg, 1 eq, 354 μmol) in i-PrOH (10 mL) was added Pd(OH)2 (24.8 mg, 0.5 eq, 177 μmol) and ammonium formate (223 mg, 176 μL, 10 eq, 3.54 mmol) under nitrogen atmosphere. The resulting mixture was stirred for 1 hour at 60 degrees C. After filtration, the filtrate was concentrated under reduced pressure to afford crude product (130 mg, 309 μmol, 87.4%) as a solid.
LCMS: m/z (ES+), [M+H]+=421.
To a solution of vinyl bromide (1.0 g, 1 eq, 2.2 mmol) and 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole (0.68 g, 1.2 eq, 2.6 mmol) in 1,4-dioxane (5 mL) and water (1 mL) was added Pd(Ph3P)4 (0.51 g, 0.2 eq, 0.44 mmol) and Cs2CO3 (2.1 g, 3 eq, 6.6 mmol). The resulting mixture was stirred for 3 hours at 80 degrees C. under nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (MeOH/DCM=1/10) to afford the product (678 mg, 1.2 mmol, 55%, 90% purity) as a semi-solid. LCMS: m/z (ES+), [M+H]+=509.30.
To a solution of olefin (400 mg, 1 eq, 786 μmol) and 1,1,2-trichloroethane (210 mg, 2 eq, 1.57 mmol) in ethyl acetate (18 mL) was added Pd/C (400 mg, 10% wt, 0.478 eq, 376 μmol) and Pd(OH)2 (400 mg, 3.62 eq, 2.85 mmol). The resulting mixture was hydrogenated at room temperature for 16 hours under hydrogen atmosphere using a hydrogen balloon. The reaction was monitored by LCMS. The mixture was filtered through a celite pad and concentrated under reduced pressure to afford the crude product (330 mg).
LCMS: m/z (ES+), [M+H]+=421.20.
To a solution of amine (700 mg, 1 eq, 1.38 mmol) and pyridin-2-yl trifluoromethanesulfonate (471 mg, 1.5 eq, 2.07 mmol) in DMSO (13 mL) was added TEA (280 mg, 385 μL, 2 eq, 2.76 mmol). The resulting mixture was stirred for 5 hours at 120 degrees C. The resulting mixture was extracted with dichloromethane (3×15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water (NH4HCO3), mobile phase B: ACN, 45% to 55% gradient in 10 min) to afford isomeric mixture of product (330 mg, 565 μmol, 40.9%) as a solid.
The isomeric mixture was separated by chiral prep-HPLC (Column: CHIRALPAK IG, 2*25 cm, m; Mobile Phase A: Hex (0.5% 2M NH3-MeOH)-HPLC, Mobile Phase B: MeOH:DCM=1:1; Flow rate: 20 mL/min; Gradient: 45% B to 45% B in 19 min) to afford N-((3R,4S)-3-((((1S,4S)-4-(1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide (101 mg, 209 μmol, 34%) as a solid.
LCMS: m/z (ES+), [M+H]+=484.
1H NMR (400 MHz, Methanol-d4) δ 8.07 (ddd, J=5.1, 2.0, 0.9 Hz, 1H), 7.97 (d, J=1.0 Hz, 1H), 7.62-7.58 (m, 1H), 7.55-7.43 (m, 2H), 7.33 (dd, J=8.7, 1.6 Hz, 1H), 6.88 (dt, J=8.7, 0.9 Hz, 1H), 6.63 (ddd, J=7.1, 5.0, 0.8 Hz, 1H), 3.88 (dq, J=12.0, 6.7, 6.1 Hz, 2H), 3.78 (dd, J=13.3, 6.8 Hz, 1H), 3.69 (dd, J=9.4, 5.9 Hz, 1H), 3.64 (d, J=4.0 Hz, 1H), 3.61-3.54 (m, 2H), 3.50-3.42 (m, 1H), 3.37 (s, 1H), 3.06 (s, 3H), 2.72-2.64 (m, 1H), 2.30 (dq, J=10.7, 7.3, 5.5 Hz, 1H), 2.09 (d, J=12.9 Hz, 2H), 1.97-1.82 (m, 4H), 1.72-1.56 (m, 4H).
To a solution of amine (80 mg, 1 eq, 0.17 mmol) in DMSO (4 mL) was added TEA (35 mg, 48 μL, 2 eq, 0.35 mmol) and 1,1,1-trifluoro-N-(pyridin-2-yl)methanesulfonamide (59 mg, 1.5 eq, 0.26 mmol). The resulting mixture was stirred for 8 hours at 120 degrees C. The reaction was monitored by LCMS, The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 0% to 55% gradient in 20 minutes and keep the gradient for 30 minutes; detector, UV 254 nm) to afford isomeric mixture of product (17 mg, 32 μmol, 18%) as a solid. Above 17 mg material was re-purified by reverse flash chromatography (column: XBridge Prep OBD C18 Column, 30*150 mm, 5 m; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 40% B to 68% B in 8 min, 68% B) to afford racemic mixture of N-((3R,4S)-3-((((1S,4S)-4-(1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)-1,1,1-trifluoromethanesulfonamide and N-((3R,4S)-3-((((1S,4S)-4-(1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)-1,1,1-trifluoromethanesulfonamide (4.1 mg, 7.6 μmol, 24%) as a solid.
LCMS: m/z (ES+), [M+H]+=538.1.
1H NMR (400 MHz, Chloroform-d) δ 8.19 (d, J=5.1 Hz, 1H), 8.04 (s, 1H), 7.87 (d, J=6.4 Hz, 1H), 7.60 (s, 1H), 7.54 (s, 1H), 7.44 (d, J=8.6 Hz, 1H), 7.31 (d, J=8.6 Hz, 1H), 6.69 (s, 2H), 4.31 (d, J=13.7 Hz, 1H), 4.06 (dq, J=22.6, 13.0 Hz, 3H), 3.78 (s, 1H), 3.68 (s, 1H), 3.18 (d, J=52.7 Hz, 2H), 2.66 (s, 1H), 2.53 (d, J=8.3 Hz, 1H), 2.09 (s, 4H), 1.76 (d, J=9.1 Hz, 6H).
To a solution of amine (300 mg, 1 eq, 713 μmol) and Et3N (144 mg, 199 μL, 2 eq, 1.43 mmol) in DMSO (5 mL) was added pyridin-2-yl trifluoromethanesulfonate (243 mg, 1.5 eq, 1.07 mmol).
The resulting mixture was stirred for 12 hours at 120 degrees C. The resulting mixture was extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (EA) to afford isomeric mixture of the product (135 mg, 271 μmol, 38.0%) as a solid. The product (135 mg) was purified by Prep-HPLC (Column: XBridge Prep OBD C18 Column, 30*150 mm, 5 m; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 39% B to 63% B in 8 min, 63% B) to afford two peaks. The more polar product (50 mg) was purified by Chiral-Prep-HPLC (Column: DZ-CHIRALPAK IG-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=60:40) to afford N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide (11.9 mg, 23.9 μmol, 24%) as a solid.
LCMS: m/z (ES+), [M+H]+=498.
1H NMR (400 MHz, Methanol-d4) δ 8.15-8.05 (m, 1H), 7.92 (d, J=0.9 Hz, 1H), 7.61-7.54 (m, 2H), 7.50-7.44 (m, 1H), 7.35 (dd, J=8.7, 1.6 Hz, 1H), 6.92-6.85 (m, 1H), 6.71-6.9 (m, 1H), 4.05 (s, 3H), 3.87-3.78 (m, 2H), 3.77-3.48 (m, 6H), 3.05 (s, 3H), 2.70-2.61 (m, 1H), 2.27-2.16 (m, 3H), 2.00-1.82 (m, 4H), 1.66-1.35 (m, 5H).
To a solution of amine (50 mg, 1 eq, 99 μmol) and 1-fluorocyclobutane-1-carboxylic acid (17 mg, 1.5 eq, 0.15 mmol) in DCM (2 mL) was added N-ethyl-N-isopropylpropan-2-amine (38 mg, 3 eq, 0.30 mmol) N,N-dimethylpyridin-4-amine (1.2 mg, 0.1 eq, 9.9 μmol) 1H-benzo[d][1,2,3]triazol-1-ol hydrate (23 mg, 1.5 eq, 0.15 mmol) and 3-(((ethylimino)methylene)amino)-N,N-dimethylpropan-1-amine (23 mg, 1.5 eq, 0.15 mmol). The resulting mixture was stirred for 2 hours at 25 degrees C. The reaction was monitored by LCMS. The resulting mixture was extracted with dichloromethane (3×5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure to afford isomeric mixture of product (58 mg, 96 umol, 97%) as an oil.
LCMS: m/z (ES+), [M+H]+=607.55.
To a stirred mixture of above tert-butyl 5-(4-(((3R,4S)-1-(1-fluorocyclobutane-1-carbonyl)-4-(methylsulfonamido)piperidin-3-yl)methoxy)cyclohexyl)-1H-indazole-1-carboxylate (78 mg, 1 eq, 0.13 mmol) in DCM (5 mL) was added a solution of TFA (1 ml) dropwise at 25 degrees C. under nitrogen atmosphere. The resulting mixture was stirred for 0.5 hours at 25 degrees C. The resulting mixture was extracted with dichloromethane (3×10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by prep-HPLC (Column: X Bridge Shield RP18 OBD Column, 30*150 mm, 5 m; Mobile Phase A: Water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 38% B to 48% B in 8 min, 48% B) followed by chiral prep-HPLC (Column: CHIRALPAK IC, 2*25 cm, 5 m; Mobile Phase A: Hex (0.5% 2M NH3-MeOH)-HPLC, Mobile Phase B: EtOH:DCM=1:1-HPLC; Flow rate: 20 mL/min; Gradient: 40% B to 40% B in 14 min) to afford desired isomer N-((3R,4S)-3-((((1S,4R)-4-(1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(1-fluorocyclobutane-1-carbonyl)piperidin-4-yl)methanesulfonamide (6 mg, 0.01 mmol, 30%, 99.5% Purity) as a solid.
LCMS: m/z (ES+), [M+H]+=507.45.
1H NMR (400 MHz, Chloroform-d) δ 8.09 (s, 1H), 7.66 (s, 1H), 7.49 (d, J=8.6 Hz, 1H), 7.37 (d, J=8.7 Hz, 1H), 6.58 (d, J=5.2 Hz, 1H), 4.06-3.83 (m, 2H), 3.82-3.59 (m, 5H), 3.46 (dd, J=56.8, 13.4 Hz, 2H), 3.01 (s, 3H), 2.72 (d, J=30.5 Hz, 3H), 2.37 (d, J=58.6 Hz, 3H), 2.17-1.86 (m, 6H), 1.72 (d, J=46.7 Hz, 6H).
To a solution of amine (70 mg, 1 eq, 0.14 mmol) in DCM (2 mL) was added pyridine (87 mg, 89 μL, 8 eq, 1.1 mmol) and triphosgene (20 mg, 0.5 eq, 69 μmol). The resulting mixture was stirred for 2 hours at 25 degrees C. Solvent was removed and MeOH (2 ml) was added to the mixture. The resulting mixture was stirred for 0.5 hours at 80 degrees C., the reaction mixture was monitored by LCMS. The crude was purified by reverse phase chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 5% to 95% gradient in 30 min; detector, UV 254 nm) to afford isomeric mixture of product (78 mg, 0.14 mmol, 100%) as a solid.
LCMS: m/z (ES+), [M+H]+=565.20.
The above mixture was purified by prep-HPLC (Column: XSelect CSH Prep C18 OBD Column, 19*250 mm, 5 m; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 37% B to 48% B in 7 min, 48% B) followed by prep-Chiral-HPLC (Column: DZ-CHIRALPAK IF-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(MeOH:DCM=1:1)=80:20) to afford methyl (3R,4S)-3-((((1S,4R)-4-(1H-indazol-5-yl)cyclohexyl)oxy)methyl)-4-(methylsulfonamido)piperidine-1-carboxylate (13.6 mg, 29.1 μmol, 39%, 99.5% Purity) as a solid.
LCMS: m/z (ES+), [M+H]+=465.35.
1H NMR (400 MHz, Chloroform-d) δ 8.08 (s, 1H), 7.66 (s, 1H), 7.49 (d, J=8.6 Hz, 1H), 7.41-7.35 (m, 1H), 6.48 (s, 1H), 3.80 (dd, J=11.2, 7.0 Hz, 4H), 3.72 (s, 3H), 3.67 (s, 2H), 3.45-3.24 (m, 2H), 3.00 (s, 3H), 2.66 (d, J=15.1 Hz, 1H), 2.26 (s, 1H), 2.09 (d, J=13.9 Hz, 2H), 1.96 (dd, J=9.0, 4.4 Hz, 1H), 1.89-1.72 (m, 5H), 1.63 (s, 2H).
To a test-tube fitted with an air-tight screw cap was added amine, TEA (24 mg, 33 μL, 2 eq, 0.24 mmol), and DMSO (2 mL) followed by pyridin-2-yl trifluoromethanesulfonate (40 mg, 1.5 eq, 0.18 mmol). The resulting mixture was stirred at 120 degrees C. for 12 hours. The reaction mixture was extracted with DCM (3×100 mL) and water. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure and purified by thin layer chromatography (PE:EA=1:1) to afford isomeric mixture of product (35 mg, 72 μmol, 61%) as a solid. This compound was re-purified by prep-HPLC (column: XBridge Prep C18 OBD Column, 30*50 mm, 5 m 13 nm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: ACN) to afford N-((3R,4S)-3-((((1S,4S)-4-(1H-benzol[d]imidazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4 yl)methanesulfonamide (3.6 mg, 7.1 μmol, 17%) as a solid.
LCMS: m/z (ES+), [M+H]+=484.20.
1H NMR (400 MHz, Chloroform-d) δ 1.28 (s, 1H), 1.55-1.67 (m, 3H), 1.78 (s, 4H), 1.83 (d, 1H), 2.05 (s, 4H), 2.09 (s, 1H), 2.40 (s, 2H), 2.69 (s, 2H), 3.04 (s, 3H), 3.44 (dd, 1H), 3.64 (s, 1H), 3.68 (dd, 1H), 3.83-3.88 (m, 1H), 3.95 (q, 2H), 4.06 (dd, 1H), 6.52 (d, 1H), 6.60-6.67 (m, 1H), 6.69 (d, 1H), 7.19 (d, 1H), 7.45-7.54 (m, 1H), 7.58-7.67 (m, 2H), 8.05 (s, 1H), 8.19 (d, 1H).
To a solution of amine (110 mg, 1 eq, 261 μmol) and pyridin-2-yl trifluoromethanesulfonate (88.9 mg, 1.5 eq, 391 μmol) in DMSO (3 mL) was added TEA (79.2 mg, 109 μL, 3 eq, 783 μmol). The resulting mixture was stirred for 6 hours at 120 degrees C. The crude was purified by reverse phase chromatography (C18 column; mobile phase A: water (NH4HCO3), mobile phase B: ACN, 40% to 55% gradient in 30 min; detector, UV 254 nm) to afford isomeric mixture of product (50 mg, 0.10 mmol, 39%) as a solid.
The crude product was purified by prep-chiral-HPLC (Column: DZ-CHIRALPAK IG-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=50:50) to afford N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-pyrazolo[3,4-c]pyridin-5-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide (18 mg, 36 μmol, 36%) as a solid.
LCMS: m/z (ES+), [M+H]+=499.
1H NMR (400 MHz, DMSO-d6) δ 9.07 (d, J=1.1 Hz, 1H), 8.09-8.04 (m, 2H), 7.51-7.43 (m, 2H), 7.22 (d, J=7.8 Hz, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.56 (dd, J=7.1, 4.9 Hz, 1H), 4.15 (s, 3H), 3.73 (dt, J=14.1, 8.5 Hz, 2H), 3.61-3.47 (m, 6H), 2.99 (s, 3H), 2.81 (ddd, J=11.5, 8.1, 3.7 Hz, 1H), 2.12 (d, J=29.1 Hz, 2H), 1.99-1.82 (m, 5H), 1.78-1.50 (m, 7H), 1.36-1.22 (m, 1H).
To a solution of amine (100 mg, 1 eq, 238 μmol) and triethylamine (48.1 mg, 66.3 μL, 2 eq, 476 μmol) in DMSO (2 mL) was added pyridin-2-yl trifluoromethanesulfonate (81.0 mg, 1.5 eq, 357 μmol). The resulting mixture was stirred for 3 hours at 120 degrees C. The reaction solution was concentrated under reduced pressure to afford the crude product. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 35% to 65% gradient) to afford racemic mixture of product (4.9 mg, 9.8 μmol, 16%) as a solid.
LCMS: m/z (ES+), [M+H]+=498.25.
1H NMR (400 MHz, Methanol-d4) δ 8.10-8.04 (m, 1H), 8.07 (s, 1H), 7.57-7.43 (m, 3H), 7.27 (dd, 1H), 6.92-6.85 (m, 1H), 6.62 (ddd, 1H), 3.90 (s, 3H), 3.86 (d, 1H), 3.77 (dd, 1H), 3.69 (dd, 1H), 3.64 (s, 1H), 3.62-3.54 (m, 2H), 3.54-3.43 (m, 1H), 3.06 (s, 3H), 2.71 (t, 1H), 2.31 (s, 1H), 2.09 (d, 2H), 2.01-1.81 (m, 4H), 1.66 (q, 4H).
To a solution of amine (130 mg, 1 eq, 309 μmol) and pyridin-2-yl trifluoromethanesulfonate (84.3 mg, 1.2 eq, 371 μmol) in DMSO (5 mL) was added TEA (93.8 mg, 129 μL, 3 eq, 927 μmol). After stirring for 3 hours at 120 degrees C. under a nitrogen atmosphere, the resulting mixture was diluted with H2O (50 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (1×50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: 8 mmol NH4HCO3, mobile phase B: ACN, 20% to 70% gradient in 30 min; detector, UV 254 nm) to afford isomeric mixture of product (minor peak 5 mg, major peak 18 mg). This isomeric mixture (18 mg) was purified by PREP-HPLC with the following conditions (Column: XBridge Prep OBD C18 Column, 30*150 mm, 5 m; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 28% B to 58% B in 8 min, 58% B) to afford enantiomeric mixture of N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-benzo[d]imidazol-6-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide and N-((3S,4R)-3-((((1S,4S)-4-(1-methyl-1H-benzol[d]imidazol-6-yl)cyclohexyl)oxy)methyl)-1-(pyridin-2-yl)piperidin-4-yl)methanesulfonamide (7.2 mg, 14 μmol, 40%) as a solid.
LCMS: m/z (ES+), [M+H]+=498.
1H NMR (400 MHz, Methanol-d4) δ 8.10-8.02 (m, 2H), 7.61-7.48 (m, 2H), 7.46 (d, 1H), 7.19 (dd, 1H), 6.91-6.84 (m, 1H), 6.70-6.59 (m, 1H), 3.89 (s, 5H), 3.82-3.43 (m, 6H), 3.06 (s, 3H), 2.81-2.68 (m, 1H), 2.38-2.29 (m, 1H), 2.10 (d, 2H), 2.01-1.85 (m, 4H), 1.76-1.58 (m, 4H), 1.41-1.23 (m, 2H), 0.96-0.86 (m, 1H).
To a solution of amine (700 mg, 1 eq, 1.48 mmol) and 2-bromopyridine (466 mg, 2 eq, 2.95 mmol) in 1,4-dioxane (36 mL) were added Cs2CO3 (1.44 g, 3 eq, 4.43 mmol) and Pd-PEPPSI-Ipent (124 mg, 0.1 eq, 148 μmol). After stirring overnight at 100 degrees C. under a nitrogen atmosphere, the resulting mixture was diluted with H2O (30 mL) and extracted with EtOAc (3×150 mL). The combined organic layers were washed with brine (3×10 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: 0.9 g/L NH4HCO3 to water, mobile phase B: ACN, 5% to 95% gradient in 30 min) to afford isomeric mixture of product (550 mg, 997 μmol, 67.6%) as a solid.
Above isomeric mixture was purified by chiral prep-HPLC (column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA): EtOH=80:20; Flow rate: 1 mL/min; Gradient: 0% B to 0% B) to afford 1,1,1-trifluoro-N-((3R,4S)-3-((((1S,4R)-4-(1-methyl-1H-indazol-5-yl) cyclohexyl) oxy) methyl)-1-(pyridin-2-yl) piperidin-4-yl) methanesulfonamide (98.5 mg, 174 μmol, 29.1%) as a solid.
LCMS: m/z (ES+), [M+H]+=552.25.
1H NMR (400 MHz, Methanol-d4) δ 8.09-8.03 (m, 1H), 7.92 (d, 1H), 7.59-7.49 (m, 2H), 7.47 (d, 1H), 7.36 (d, 1H), 6.91 (d, 1H), 6.65 (dd, 1H), 4.05 (d, 3H), 4.01 (d, 1H), 3.88 (ddd, 2H), 3.66-3.60 (m, 2H), 3.59-3.51 (m, 2H), 3.44 (dd, 1H), 2.69 (t, 1H), 2.32 (s, 1H), 2.14-2.03 (m, 2H), 1.99-1.79 (m, 4H), 1.65 (q, 4H), 1.34-1.28 (m, 1H).
To a solution of amine (220.00 mg, 1 eq, 523.10 μmol) and N-ethyl-N-isopropylpropan-2-amine (202.83 mg, 3 eq, 1.5693 mmol) in DCM (15 mL) were added 1H-benzo[d][1,2,3]triazol-1-ol (106.03 mg, 1.5 eq, 784.65 μmol), 3-(((ethylimino)methylene)amino)-N,N-dimethylpropan-1-amine hydrochloride (150.4 mg, 1.5 eq, 784.65 μmol) and 1-fluorocyclobutane-1-carboxylic acid (61.783 mg, 1 eq, 523.10 μmol), the resulting mixture was stirred for 2 hours at 25 degrees C. The resulting mixture was extracted with DCM (3×10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 60% to 80% gradient in 10 min; detector, UV 254 nm) to afford isomeric mixture of product (200.00 mg, 384.13 μmol, 73%) as an oil. This isomeric mixture was purified by Prep Chiral-HPLC (column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=60:40; Flow rate: 1 mL/min; Gradient: 0% B to 0% B) to afford N-((3R,4S)-1-(1-fluorocyclobutane-1-carbonyl)-3-((((1S,4R)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (65.00 mg, 124.8 μmol, 32.50%) as a solid.
LCMS: m/z (ES+), [M+H]+=521.20.
1H NMR (400 MHz, Methanol-d4) δ 7.92 (s, 1H), 7.62 (d, J=16.1 Hz, 1H), 7.49-7.35 (m, 2H), 4.05 (d, J=2.0 Hz, 4H), 3.97-3.77 (m, 2H), 3.74-3.58 (m, 3H), 3.49 (q, J=9.0 Hz, 2H), 3.37 (s, 1H), 3.04 (d, J=4.0 Hz, 3H), 2.73 (s, 3H), 2.07 (d, J=14.9 Hz, 3H), 1.90 (dd, J=19.0, 9.3 Hz, 5H), 1.65 (d, J=9.5 Hz, 5H).
To the solution of amine (HCl salt) (400 mg, 1 eq, 875 μmol) in DCM (5 mL) were added pyridine (208 mg, 212 μL, 3 eq, 2.63 mmol) and triphosgene (130 mg, 0.5 eq, 438 μmol) at room temperature. The solution was stirred for 2 hours at 25 degrees C. The mixture was concentrated under reduced pressure. The residue was re-dissolved in the MeOH (28.0 g, 35.4 mL, 1000 eq, 875 mmol) and the resulting solution was heated to 80 degrees C. and stirred for 30 minutes. The mixture was monitored by LCMS. The reaction mixture was concentrated under reduced pressure. The residue was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 0% to 70% gradient) to afford crude as a mixture of 4 isomers (350 mg, 731 μmol, 83.6%) as a solid. The mixture was purified by prep-Chiral HPLC (column: CHIRALPAK IC, 2*25 cm, 5 m; Mobile Phase A: Hex (0.5% 2M NH3-MeOH)-HPLC, Mobile Phase B: EtOH:DCM=1:1) to afford methyl (3R,4S)-3-((((1S,4R)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-4 (methylsulfonamido)piperidine-1-carboxylate (60 mg, 0.13 mmol, 17%) as a solid.
LCMS: m/z (ES+), [M+H]+=479.25.
1H NMR (SNB06-439):(400 MHz, Methanol-d4) δ 7.93 (d, J=1.0 Hz, 1H), 7.61 (s, 1H), 7.47 (d, J=8.9 Hz, 1H), 7.39 (d, J=8.8 Hz, 1H), 4.05 (s, 3H), 3.81 (s, 1H), 3.65 (d, J=22.4 Hz, 10H), 3.03 (s, 3H), 2.69 (d, J=12.1 Hz, 1H), 2.19 (s, 1H), 2.10 (s, 2H), 1.90 (s, 2H), 1.80 (s, 2H), 1.74-1.57 (m, 4H).
To a solution of amine (150 mg, 1 eq, 316 μmol) and 3-bromopyridazine (101 mg, 2 eq, 632 μmol) in 1,4-dioxane (2 mL) was added PEPPSI-Pd (26.6 mg, 0.1 eq, 31.6 μmol) and Cs2CO3 (309 mg, 3 eq, 948 μmol). The resulting mixture was stirred for 3 hours at 100 degrees C. The reaction was monitored by LCMS. The resulting mixture was extracted with ethyl acetate (3×30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (EA/PE=2/1) to afford isomeric mixture of product (140 mg, 155 μmol, 49.0%) as a solid. The crude product was purified by prep-HPLC (column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=60:40) to afford 1,1,1-trifluoro-N-((3R,4S)-3-((((1S,4R)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridazin-3-yl)piperidin-4-yl)methanesulfonamide (115 mg, 207 μmol, 76.7%) as a solid.
LCMS: m/z (ES+), [M+H]+=553.25.
1H NMR (400 MHz, Methanol-d4) δ 8.07 (s, 1H), 7.51 (d, J=1.6 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.25 (dd, J=8.4, 1.6 Hz, 1H), 3.89 (s, 3H), 3.87-3.82 (m, 1H), 3.78-3.65 (m, 2H), 3.65-3.54 (m, 1H), 3.51 (d, J=9.4 Hz, 1H), 3.46-3.35 (m, 2H), 3.03 (s, 3H), 2.83-2.60 (m, 3H), 2.46 (dq, J=22.5, 10.2 Hz, 2H), 2.28-2.04 (m, 3H), 2.02-1.89 (m, 3H), 1.84 (d, J=13.4 Hz, 2H), 1.62 (q, J=13.5, 12.6 Hz, 3H), 1.55-1.33 (m, 3H).
To a solution of amine (HCl salt) (260 mg, 1 eq, 548 μmol) and 1-fluorocyclobutane-1-carboxylic acid (77.7 mg, 1.2 eq, 657 μmol) in DCM (6 mL) was added DIPEA (212 mg, 286 μL, 3 eq, 1.64 mmol) and HOBt (126 mg, 1.5 eq, 822 μmol) and 3-(((ethylimino)methylene)amino)-N,N-dimethylpropan-1-amine hydrochloride (158 mg, 1.5 eq, 822 μmol). The resulting mixture was stirred for 2 hours at 25 degrees C. The mixture was concentrated under reduced pressure to afford the crude product. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 5% to 95% gradient in 30 min) to afford crude product as a mixture of 4 isomers (260 mg, 452 μmol, 82.6%) as a solid. The isomer mixtures was purified by chiral prep-HPLC (Column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=70:30) to afford desired isomer 1,1,1-trifluoro-N-((3R,4S)-1-(1-fluorocyclobutane-1-carbonyl)-3-((((1S,4R)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (48.4 mg, 83.6 μmol, 17.8%) as a solid.
LCMS: m/z (ES+), [M+Na]+=597.15.
1H NMR (400 MHz, Chloroform-d) δ 7.96 (s, 1H), 7.85 (dd, J=15.6, 6.4 Hz, 1H), 7.57 (d, J=1.3 Hz, 1H), 7.42-7.31 (m, 2H), 4.38 (dd, J=26.6, 13.9 Hz, 1H), 4.09 (s, 3H), 3.99-3.65 (m, 5H), 3.33-3.02 (m, 2H), 2.97-2.74 (m, 1H), 2.70-2.58 (m, 2H), 2.46 (dq, J=22.9, 12.5 Hz, 4H), 2.12-1.89 (m, 5H), 1.76 (s, 1H), 1.68 (dd, J=24.1, 13.9 Hz, 4H).
To a solution of amine (450 mg, 1 eq, 1.07 mmol) and 3-bromo-pyridazine (255 mg, 148 μL, 1.5 eq, 1.60 mmol) in 1,4-dioxane (18 mL) were added Cs2CO3 (1.05 g, 3 eq, 3.21 mmol) and Pd-PEPPSI (89.9 mg, 0.1 eq, 107 μmol). After stirring for 3 hours at 100 degrees C. under a nitrogen atmosphere. The resulting mixture was diluted with H2O (10 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (3×10 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: 0.9 g/L NH4HCO3 to water, mobile phase B: ACN, 5% to 95% gradient in 30 min) to afford isomeric mixture of product (330 mg, 662 μmol, 62%) as a solid.
The above isomeric mixture was purified by chiral HPLC (Column: DZ-CHIRALPAK IF-3, 4.6*50 mm, 3.0 m; Mobile Phase A: MtBE (0.2% DEA):(MeOH:DCM=1:1)=85:15; Flow rate: 1 mL/min; Gradient: 0% B to 0% B) to afford N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl) cyclohexyl) oxy) methyl)-1-(pyridazin-3-yl) piperidin-4-yl) methanesulfonamide (69.5 mg, 139 μmol, 38.5%) as a solid.
LCMS: m/z (ES+), [M+H]+=499.25.
1H NMR (400 MHz, DMSO-d6) δ 8.52 (dd, 1H), 7.96 (d, 1H), 7.56-7.49 (m, 2H), 7.35-7.21 (m, 4H), 4.01 (s, 3H), 3.88 (dt, 1H), 3.74 (dd, 2H), 3.70-3.48 (m, 4H), 3.38 (d, 1H), 3.00 (s, 3H), 2.69-2.58 (m, 1H), 2.14 (s, 1H), 1.95 (t, 2H), 1.85-1.66 (m, 4H), 1.62-1.44 (m, 4H).
To a solution of amine (300.0 mg, 1 eq, 713.3 μmol) and 1-fluorocyclobutane-1-carboxylic acid (101.1 mg, 1.2 eq, 856.0 μmol) in DCM (8 mL) was added 1H-benzo[d][1,2,3]triazol-1-ol hydrate (163.9 mg, 1.5 eq, 1.070 mmol), EDC (205.1 mg, 1.5 eq, 1.070 mmol) and DIEA (276.6 mg, 373 μL, 3 eq, 2.140 mmol). The resulting mixture was stirred for 2 hours at 25 degrees C.
The reaction was monitored by LCMS. The resulting mixture was extracted with dichloromethane (3×30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (MeOH/DCM=1/12) to afford isomeric mixture of product (190 mg, 324 μmol, 45.4%) as a solid.
The crude product was purified by prep-CHIRAL-HPLC (Column: CHIRALPAK IC, 2*25 cm, 5 μm; Mobile Phase A: Hex (0.5% 2M NH3-MeOH)-HPLC, Mobile Phase B: EtOH:DCM=1:1-HPLC; Flow rate: 20 mL/min; Gradient: 70% B to 70% B in 11 min) to afford N-((3R,4S)-1-(1-fluorocyclobutane-1-carbonyl)-3-((((1S,4S)-4-(1-methyl-1H-benzo[d]imidazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (49.6 mg, 94.4 μmol, 25%) as a solid.
LCMS: m/z (ES+), [M+H]+=521.30.
1H NMR (400 MHz, Methanol-d4) δ 8.06 (d, J=3.2 Hz, 1H), 7.54 (s, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.36-7.25 (m, 1H), 3.89 (d, J=1.3 Hz, 4H), 3.74 (s, 1H), 3.72-3.58 (m, 3H), 3.49 (q, J=9.1, 8.4 Hz, 2H), 3.04 (d, J=5.6 Hz, 3H), 2.82-2.64 (m, 3H), 2.48 (d, J=20.9 Hz, 2H), 2.31-1.99 (m, 3H), 2.00-1.75 (m, 6H), 1.75-1.53 (m, 5H).
To a stirred solution of amine (80 mg, 1 eq, 0.19 mmol) and (R)-tetrahydrofuran-3-carboxylic acid (33 mg, 1.5 eq, 0.29 mmol) in DCM (2 mL) was added 1H-benzo[d][1,2,3]triazol-1-ol hydrate (44 mg, 1.5 eq, 0.29 mmol), 3-(((ethylimino)methylene)amino)-N,N-dimethylpropan-1-amine hydrochloride (55 mg, 1.5 eq, 0.29 mmol) and DIPEA (74 mg, 99 μL, 3 eq, 0.57 mmol) in portions at 25 degrees C. under nitrogen atmosphere. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 0% to 100% gradient in 30 min; detector, UV 220 nm) to afford isomeric mixture of product (90 mg, 0.17 mmol, 91%) as an oil. The crude product (100 mg) was purified by Prep-Chiral-HPLC (Column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=30:70) to afford N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-((R)-tetrahydrofuran-3-carbonyl)piperidin-4-yl)methanesulfonamide (30 mg, 58 μmol, 30%) as a solid.
LCMS: m/z (ES+), [M+H]+=519.3.
1H NMR (400 MHz, Methanol-d4) δ 7.93 (d, 1H), 7.61 (d, 1H), 7.47 (dd, 1H), 7.38 (ddd, 1H), 4.05 (d, 3H), 4.01-3.72 (m, 7H), 3.71-3.45 (m, 6H), 3.04 (d, 3H), 2.70 (q, 1H), 2.31-1.97 (m, 5H), 1.95-1.55 (m, 8H).
To a solution of amine (80.0 mg, 1 eq, 190 μmol), HOBt (43.7 mg, 1.5 eq, 285 μmol) and EDC (54.7 mg, 1.5 eq, 285 μmol) in DCM (2 mL) was added DIEA (49.2 mg, 66.3 μL, 2 eq, 380 μmol) and cyclopropanecarboxylic acid (24.6 mg, 1.5 eq, 285 μmol). The resulting mixture was stirred for 2 hours at 25 degrees C. The reaction was concentrated under reduced pressure.
The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 30% to 60% gradient in 20 min; detector, UV 254 nm) to afford isomeric mixture of product (90.0 mg, 184 μmol, 96.8%) as an oil. The crude product (95 mg) was purified by prep-chiral-HPLC (Column: DZ-CHIRALPAK IG-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(IPA:DCM=1:1)=55:45) to afford N-((3R,4S)-1-(cyclopropanecarbonyl)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (37.0 mg, 75.7 μmol, 39%) as a solid.
LCMS: m/z (ES+), [M+H]+=489.20.
1H NMR (400 MHz, Methanol-d4) δ 7.93 (d, 1H), 7.59 (d, 1H), 7.46 (d, 1H), 7.38 (dd, 1H), 4.05 (s, 4H), 3.94-3.77 (m, 2H), 3.68 (d, 3H), 3.50 (dd, 1H), 3.05 (d, 3H), 2.70 (d, 1H), 2.33-2.02 (m, 4H), 1.97-1.83 (m, 3H), 1.78-1.59 (m, 5H), 0.96-0.77 (m, 4H).
To a solution of amine (330 mg, 1 eq, 785 μmol) in DCM (14 mL) was added 3 (((ethylimino) methylene) amino)-N, N-dimethylpropan-1-amine hydrochloride (226 mg, 1.5 eq, 1.18 mmol) and DIEA (304 mg, 410 μL, 3 eq, 2.35 mmol) and HOBt (180 mg, 1.5 eq, 1.18 mmol) and 1-fluorocyclobutanecarboxylic acid (111 mg, 1.2 eq, 942 μmol). The resulting mixture was stirred for 2 hours at room temperature. The filtrate was concentrated under reduced pressure.
The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 5% to 95% gradient in 30 min; detector, UV 254 nm) to afford isomeric mixture of product (68 mg, 0.13 mmol, 17%) as a solid.
The isomeric mixture was purified by CHIRAL-HPLC (Column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 m; Mobile Phase A: MtBE (0.2% DEA):(MeOH:DCM=1:1)=75:25; Flow rate: 1 mL/min; Gradient: 0% B to 0% B) to afford N-((3R,4S)-1-(1-fluorocyclobutane-1-carbonyl)-3-((((1S,4S)-4-(1-methyl-1H-benzo[d]imidazol-6-yl) cyclohexyl) oxy) methyl) piperidin-4-yl) methanesulfonamide (7.6 mg, 14 μmol, 27%) as a solid.
LCMS: m/z (ES+), [M+H]+=521.25.
1H NMR (400 MHz, Methanol-d4) δ 8.07 (d, 1H), 7.57 (dd, 1H), 7.49 (d, 1H), 7.26-7.19 (m, 1H), 3.91 (d, 5H), 3.77-3.59 (m, 3H), 3.52 (dd, 2H), 3.39 (d, 2H), 3.05 (d, 3H), 2.85-2.65 (m, 3H), 2.45 (tp, 2H), 2.32-2.04 (m, 3H), 2.02-1.78 (m, 5H), 1.75-1.53 (m, 5H).
To a stirred solution of amine (70 mg, 1 eq, 0.17 mmol) in DCM (2 mL) was added triethylamine (51 mg, 3 eq, 0.50 mmol) and acetic anhydride (34 mg, 2 eq, 0.33 mmol) dropwise at 25 degrees C. under nitrogen atmosphere. The residue was purified by Prep-TLC (CH2Cl2/MeOH 10:1) to afford isomeric mixture of product (70 mg, 0.11 mmol, 64%) as a solid. The crude product (78 mg) was purified by Prep-Chiral-HPLC (Column: DZ-CHIRALPAK 1H-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=60:40) to afford N-((3R,4S)-1-acetyl-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (23.2 mg, 48.1 μmol, 29%) as a solid.
LCMS: m/z (ES+), [M+H]+=463.2.
1H NMR (400 MHz, Methanol-d4) δ 7.93 (s, 1H), 7.60 (d, 1H), 7.47 (d, 1H), 7.42-7.34 (m, 1H), 4.09-3.94 (m, 4H), 3.82 (dd, 2H), 3.73-3.61 (m, 3H), 3.52 (dd, 2H), 3.38 (d, 1H), 3.04 (d, 3H), 2.69 (t, 1H), 2.31-2.04 (m, 6H), 1.90 (d, 3H), 1.71 (ddd, 16.6, 9.0 Hz, 5H), 0.11 (d, 1H).
To a stirred solution of amine (65 mg, 1 eq, 0.15 mmol) and 2-hydroxy-2-methylpropanoic acid (48 mg, 3 eq, 0.46 mmol) in DCM (2 mL) was added 1H-benzo[d][1,2,3]triazol-1-ol hydrate (71 mg, 3 eq, 0.46 mmol) EDC (89 mg, 3 eq, 0.46 mmol) DIEA (0.12 g, 0.16 mL, 6 eq, 0.93 mmol) in portions at 25 degrees C. under nitrogen atmosphere. The residue was purified by Preparative-TLC (CH2Cl2/MeOH 10:1) to afford isomeric mixture of product (70 mg, 0.14 mmol, 89%) as a solid. The crude product (70 mg) was purified by Prep-Chiral-HPLC (Column: DZ-CHIRALPAK IG-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=60:40) to afford N-((3R,4S)-1-(2-hydroxy-2-methylpropanoyl)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (25.1 mg, 48 μmol, 35%,) as a solid.
LCMS: m/z (ES+), [M+H]+=507.3.
1H NMR (400 MHz, Methanol-d4) δ 7.92 (s, 1H), 7.63 (s, 1H), 7.46 (d, 1H), 7.43-7.38 (m, 1H), 4.05 (s, 4H), 3.88 (d, 1H), 3.70-3.59 (m, 3H), 3.51 (dd, 1H), 3.04 (s, 3H), 2.69 (t, 1H), 2.22 (s, 1H), 2.16-2.03 (m, 2H), 1.91 (d, 4H), 1.67 (d, 4H), 1.47 (s, 6H), 1.31 (s, 2H), 0.12 (s, 1H).
To a solution of amine (100 mg, 1 eq, 238 μmol) and TEA (72.2 mg, 99.4 μL, 3 eq, 713 μmol) in DCM (1.5 mL) was added trimethylacetyl chloride (34.4 mg, 35.0 μL, 1.2 eq, 285 μmol). The resulting mixture was stirred for 30 minutes at room temperature. The residue was purified by Prep-TLC (EA/PE=1/3) to afford crude as a solid. The filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: 0.9 g/L NH4HCO3 aqueous solution, mobile phase B: ACN, 5% to 95%) to afford isomeric mixture of product (80 mg, 0.16 mmol, 67%) as a solid.
The crude product was purified by prep-CHIRAL-HPLC (Column: DZ-CHIRALPAK IF-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=80:20) to afford N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl) cyclohexyl) oxy) methyl)-1-pivaloylpiperidin-4-yl) methanesulfonamide (30.7 mg, 60.5 μmol, 38%) as a solid.
LCMS: m/z (ES+), [M+H]+=505.25.
1H NMR (400 MHz, DMSO-d6) δ 7.93 (s, 1H), 7.55-7.52 (m, 2H), 7.29 (dd, 2H), 4.01 (s, 3H), 3.93 (s, 2H), 3.75-3.68 (m, 1H), 3.59 (s, 1H), 3.43 (dd, 1H), 3.38 (s, 2H), 3.30 (s, 1H), 2.96 (s, 3H), 2.64 (d, 1H), 1.96 (dd, 3H), 1.75-1.50 (m, 8H).
To a solution of amine (100 mg, 1 eq, 238 μmol) and TEA (120 mg, 166 μL, 5 eq, 1.19 mmol) in DCM (1.5 mL) was added triphosgene (42.3 mg, 26 μL, 0.6 eq, 143 μmol). The resulting mixture was stirred for 30 minutes at 0 degrees C. To the above mixture was added a solution of azetidine hydrochloride (26.7 mg, 1.2 eq, 285 μmol) in DCM (0.2 mL) dropwise over 1 minute at degrees C. under nitrogen atmosphere. The resulting mixture was stirred for an additional 1 hour at room temperature. The crude product was purified by prep-HPLC (XBridge Prep OBD C18 Column, 30*150 mm, 5 m; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 28% B to 48% B in 8 min, 48% B; Wavelength: 254 nm). Solvents were evaporated to afford isomeric mixture of product (60 mg, 0.12 mmol, 50%) as a solid.
The above isomeric mixture was purified by prep-CHIRAL-HPLC (CHIRALPAK IE-3, 4.6*50 mm; Mobile Phase A: MtBE (0.2% DEA): EtOH=80:20; Flow rate: 1 mL/min; Gradient: 0% B to 0% B) to afford N-((3R,4S)-1-(azetidine-1-carbonyl)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl) cyclohexyl) oxy) methyl) piperidin-4-yl) methanesulfonamide (22.4 mg, 43.3 μmol, 36%) as a solid.
LCMS: m/z (ES+), [M+H]+=504.30.
1H NMR (400 MHz, Chloroform-d) δ 7.96 (s, 1H), 7.60 (s, 1H), 7.37 (d, 2H), 6.44 (d, 1H), 4.09 (s, 3H), 4.05-3.97 (m, 4H), 3.80 (td, 2H), 3.70-3.59 (m, 4H), 3.31 (dd, 1H), 3.17 (td, 1H), 3.00 (s, 3H), 2.67 (dq, 1H), 2.25 (p, 3H), 2.12-2.02 (m, 2H), 1.95 (dtd, 1H), 1.89-1.73 (m, 5H), 1.68-1.53 (m, 2H).
To a solution of amine (120.0 mg, 1 eq, 252.9 μmol) and 2-fluoropyrimidine (29.76 mg, 1.2 eq, 303.5 μmol) in DMSO (1.2 mL) was added K2CO3 (87.37 mg, 2.5 eq, 632.2 μmol). The resulting mixture was stirred for 2 hours at 100 degrees C. The reaction was monitored by LCMS. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: NH4HCO3, mobile phase B: ACN, 5% to 100% gradient in 30 minutes and keep 61.5% gradient in 8 minutes) to afford 1,1,1-trifluoro-N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyrimidin-2-yl)piperidin-4-yl)methanesulfonamide (117.1 mg, 210 μmol, 83.2%, 99.3% purity) as a solid.
LCMS: m/z (ES+), [M+H]+=553.25.
1H NMR (400 MHz, Chloroform-d) δ 8.34 (d, J=4.8 Hz, 2H), 7.96 (s, 1H), 7.86 (d, J=6.4 Hz, 1H), 7.56 (s, 1H), 7.42-7.30 (m, 2H), 6.55 (t, J=4.7 Hz, 1H), 4.68 (t, J=13.1 Hz, 2H), 4.07 (s, 3H), 4.01 (s, 1H), 3.91 (t, J=9.9 Hz, 1H), 3.78 (dd, J=9.8, 3.8 Hz, 1H), 3.71-3.62 (m, 1H), 3.36 (d, J=13.9 Hz, 1H), 3.29-3.13 (m, 1H), 2.75-2.58 (m, 1H), 2.52 (t, J=5.8 Hz, 1H), 2.19-1.95 (m, 4H), 1.88-1.66 (m, 4H), 1.66-1.52 (m, 2H).
To a solution of amine (120.0 mg, 1 eq, 252.9 μmol) and 2-fluoropyrazine (49.60 mg, 2 eq, 505.8 μmol) in DMSO (1 mL) was added K2CO3 (104.8 mg, 3 eq, 758.6 μmol). The resulting mixture was stirred for 16 hours at 25 degrees C. The reaction was monitored by LCMS. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water (5 mmol NH4HCO3), mobile phase B: ACN, 5% to 95% gradient in 30 min; detector, UV 254 nm) to afford isomeric mixture of product (119.4 mg, 213 μmol, 87%) as a solid.
LCMS: m/z (ES+), [M+H]+=553.3.
1H NMR (400 MHz, Chloroform-d) δ 8.18 (s, 1H), 8.11 (d, J=2.3 Hz, 1H), 7.93 (d, J=0.9 Hz, 1H), 7.89 (s, 1H), 7.82 (d, J=6.3 Hz, 1H), 7.56 (s, 1H), 7.38-7.29 (m, 2H), 4.33-4.25 (m, 1H), 4.19 (d, J=13.8 Hz, 1H), 4.07 (s, 3H), 4.04-3.91 (m, 2H), 3.76 (dd, J=9.8, 3.9 Hz, 1H), 3.68 (t, J=2.9 Hz, 1H), 3.33 (dd, J=13.8, 3.4 Hz, 1H), 3.21 (ddd, J=13.7, 9.1, 4.8 Hz, 1H), 2.71-2.62 (m, 1H), 2.54 (t, J=5.0 Hz, 1H), 2.17-2.00 (m, 4H), 1.82-1.69 (m, 4H), 1.59 (s, 2H).
To a solution of amine (800 mg, 80% wt, 1 eq, 1.30 mmol) and 3-bromopyridazine (620 mg, 3 eq, 3.90 mmol) and PEPPSI-pd (111 mg, 0.1 eq, 130 μmol) and Cs2CO3 (1.27 g, 3 eq, 3.90 mmol) in DMSO (5 mL). The resulting mixture was stirred for 8 hours at 120 degrees C. The resulting mixture was extracted with ethyl acetate/water (3×100 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (EA) to afford crude product (220 mg, 386 μmol, 30%) as a solid. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water (NH4HCO3), mobile phase B: ACN, 5% to 95% gradient in 30 min; detector, UV 220 nm) to afford isomeric mixture of product (150 mg, 263 μmol, 58%) as a solid. This isomeric mixture was further purified by reverse flash chromatography (Column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 m; Mobile Phase A: MtBE (0.2% DEA):(EtOH:DCM=1:1)=70:30) to afford 1,1,1-trifluoro-N-((3R,4S)-3-((((1S,4S)-4-(7-fluoro-1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridazin-3-yl)piperidin-4-yl)methanesulfonamide (21.9 mg, 38.4 μmol, 23%) as a solid.
LCMS: m/z (ES+), [M+H]+=571.20.
1H NMR (400 MHz, Methanol-d4) δ 8.45 (dd, J=4.2, 1.4 Hz, 1H), 7.96 (d, J=2.3 Hz, 1H), 7.40-7.29 (m, 3H), 7.05 (dd, J=13.5, 1.3 Hz, 1H), 4.20 (d, J=0.9 Hz, 3H), 4.07 (dq, J=11.7, 5.9 Hz, 2H), 3.90 (dt, J=12.7, 6.3 Hz, 1H), 3.76-3.46 (m, 5H), 3.06 (q, J=7.3 Hz, 3H), 2.67 (t, J=12.0 Hz, 1H), 2.33 (s, 1H), 2.09 (d, J=12.8 Hz, 2H), 1.99-1.76 (m, 4H), 1.74-1.55 (m, 4H), 1.31 (t, J=7.3 Hz, 5H).
To a solution of amine (80 mg, 1 eq, 0.19 mmol) and thiazole-5-carboxylic acid (37 mg, 1.5 eq, 0.29 mmol) in DCM (3 mL) was added HOBt (44 mg, 1.5 eq, 0.29 mmol), EDC (55 mg, 1.5 eq, 0.29 mmol) and DIEA (74 mg, 99 μL, 3 eq, 0.57 mmol). The resulting mixture was stirred for 2 hours at 25 degrees C. The reaction was monitored by LCMS. The resulting mixture was extracted with dichloromethane (3×15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water, mobile phase B: ACN, 25% to 60% gradient in 30 min; detector, UV 254 nm) to afford isomeric mixture of product (50 mg, 94 μmol, 49%) as a solid.
Above isomeric mixture (50 mg) was purified by CHIRAL-HPLC (Column: DZ-CHIRALPAK IC-3, 4.6*50 mm, 3.0 m; Mobile Phase A: Hex (0.2% DEA):(EtOH:DCM=1:1)=35:65) to afford N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(thiazole-5-carbonyl)piperidin-4-yl)methanesulfonamide (21.6 mg, 40.6 μmol, 43%) as a solid.
LCMS: m/z (ES+), [M+H]+=532.20.
1H NMR (400 MHz, Methanol-d4) δ 9.10 (s, 1H), 8.25 (s, 1H), 7.93 (s, 1H), 7.54 (s, 1H), 7.45 (d, 1H), 7.32 (s, 1H), 4.04 (s, 3H), 3.95-3.84 (m, 4H), 3.72-3.44 (m, 3H), 3.04 (s, 3H), 2.62 (d, 1H), 2.17 (d, 3H), 1.97-1.53 (m, 9H).
To a solution of amine (50 mg, 1 eq, 0.12 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCl) (34 mg, 1.5 eq, 0.18 mmol), 3-methyltetrahydrofuran-3-carboxylic acid (31 mg, 2 eq, 0.24 mmol) and 1-hydroxy-1H-benzotriazole (24 mg, 25 μL, 1.5 eq, 0.18 mmol) and diisopropylethylamine (46 mg, 61 μL, 3 eq, 0.36 mmol) in DCM (1 mL). The resulting mixture was stirred for 2 hours at 25 degrees C. The crude was purified by reverse flash chromatography (C18 column; mobile phase A: water (NH4HCO3), mobile phase B: ACN, 5% to 95% gradient in 30 min) to afford crude product as a mixture of isomers (60 mg, 0.11 mmol, 95%) as a solid. The isomeric mixture was purified by prep-HPLC (column: CHIRALPAK IC, 2*25 cm, 5 m; Mobile Phase A: Hex (0.5% 2M NH3-MeOH) to afford desired isomer N-((3R,4S)-3-((((1S,4R)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-((S)3-methyltetrahydrofuran-3-carbonyl)piperidin-4-yl)methanesulfonamide (10.8 mg, 12%) as a solid.
LCMS: m/z (ES+), [M+H]+=533.20.
1H NMR (400 MHz, Methanol-d4) δ 7.91 (d, J=0.9 Hz, 1H), 7.58 (s, 1H), 7.45 (d, J=8.7 Hz, 1H), 7.36 (d, J=8.8 Hz, 1H), 4.08 (d, J=8.9 Hz, 1H), 4.03 (s, 3H), 3.83 (ddt, J=22.4, 8.5, 4.6 Hz, 4H), 3.68-3.62 (m, 2H), 3.59 (dd, J=9.5, 5.3 Hz, 1H), 3.47 (t, J=8.9 Hz, 1H), 3.01 (s, 3H), 2.68 (t, J=12.3 Hz, 1H), 2.42 (q, J=10.4, 9.2 Hz, 1H), 2.25-2.13 (m, 1H), 2.07 (t, J=14.3 Hz, 2H), 2.01-1.75 (m, 5H), 1.64 (dd, J=21.1, 9.0 Hz, 4H), 1.41 (s, 3H), 0.10 (s, 1H).
To a solution of amine (150.0 mg, 1 eq, 288.1 μmol) and TEA (87.45 mg, 120 μL, 3 eq, 864.3 μmol) in DCM (8 mL) was added methylsulfamoyl chloride (74.65 mg, 2 eq, 576.2 μmol). The resulting mixture was stirred for 16 hours at 25 degrees C. The residue was purified by Prep-TLC (MeOH/DCM=1/12) to afford mixture of 4 isomers (120.0 mg, 233.6 μmol, 81.09%) as an oil. The isomers were separated by prep-Chiral-HPLC (conditions: Column: CHIRALPAK 1H, 2*25 cm, 5 m; Mobile Phase A: Hex (0.5% 2M NH3-MeOH)-HPLC, Mobile Phase B: IPA:DCM=1:1-HPLC; Flow rate: 20 mL/min; Gradient: 40% B to 40% B in 16.5 min) to afford desired isomer N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridazin-3-yl)piperidin-4-yl)methylsulfamide (24.4 mg, 47.3 μmol, 20.3%, 99.6% purity) as a solid.
LCMS: m/z (ES+), [M+H]+=514.20.
1H NMR (400 MHz, Chloroform-d) δ 8.58 (d, J=4.4 Hz, 1H), 7.94 (s, 1H), 7.60 (s, 1H), 7.36 (d, J=1.2 Hz, 3H), 7.19 (d, J=9.4 Hz, 1H), 6.44 (d, J=4.7 Hz, 1H), 4.30 (d, J=5.6 Hz, 1H), 4.07 (s, 5H), 3.96-3.80 (m, 3H), 3.74 (dd, J=9.9, 3.8 Hz, 1H), 3.67 (s, 1H), 3.55 (s, 1H), 2.79 (d, J=5.3 Hz, 3H), 2.74-2.63 (m, 1H), 2.39 (s, 1H), 2.19 (s, 1H), 2.06 (t, J=13.1 Hz, 2H), 1.94 (s, 1H), 1.84 (d, J=11.9 Hz, 4H), 1.61 (m, J=13.7 Hz, 2H).
To a solution of amine (200.0 mg, 1 eq, 475.6 μmol) and triethylamine (288.7 mg, 6 eq, 2.853 mmol) in DCM (2 mL) was added dimethylsulfamoyl chloride (136.6 mg, 2 eq, 951.1 μmol). The resulting mixture was stirred for 16 hours at 25 degrees C. The residue was purified by Prep-TLC (MeOH/DCM=1/12) to afford a mixture of 4 isomers (81.0 mg, 153 μmol, 32.4%) as a solid. The isomers were separated by prep-Chiral-HPLC (column: CHIRALPAK IG, 2*25 cm, 5 m; Mobile Phase A: Hex (0.5% 2M NH3-MeOH)-HPLC, Mobile Phase B: EtOH:DCM=1:1-HPLC; Flow rate: 20 mL/min; Gradient: 50% B to 50% B in 23 min) to afford N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridazin-3-yl)piperidin-4-yl)dimethylsulfamide (15.3 mg, 28.9 μmol, 18.9%, 99.8% purity) as a solid.
LCMS: m/z (ES+), [M+H]+=528.30.
1H NMR (400 MHz, Chloroform-d) δ 8.56 (d, J=4.4 Hz, 1H), 7.91 (s, 1H), 7.56 (d, J=1.3 Hz, 1H), 7.33 (d, J=1.2 Hz, 2H), 7.20 (dd, J=9.3, 4.4 Hz, 1H), 6.94 (dd, J=9.3, 1.2 Hz, 1H), 6.38 (d, J=5.5 Hz, 1H), 4.23-4.11 (m, 1H), 4.04 (s, 4H), 3.86 (dd, J=9.8, 7.7 Hz, 1H), 3.78 (m, J=9.1, 4.2 Hz, 1H), 3.74-3.59 (m, 3H), 3.48 (s, 1H), 3.35 (m, J=12.9, 8.6, 3.6 Hz, 1H), 2.83 (s, 6H), 2.64 (m, J=11.6, 3.7 Hz, 1H), 2.45-2.32 (m, 1H), 2.17-2.00 (m, 4H), 1.95 (m, J=9.9, 6.3, 3.5 Hz, 1H), 1.81 (m, J=24.7, 13.9, 10.7 Hz, 4H), 1.66-1.49 (m, 2H).
To a solution of (3R,4S)-3-(((4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)-1-(pyridazin-3-yl)piperidin-4-amine (90.0 mg, 1 eq, 214 μmol) and TEA (130 mg, 179 μL, 6 Eq, 1.28 mmol) in DCM (6 mL) was added dimethylcarbamic chloride (34.5 mg, 1.5 Eq, 321 μmol). The resulting mixture was stirred for 16 hours at 25 degrees C. The residue was purified by Prep-TLC (MeOH/DCM=1/12) to afford crude product (85.0 mg, 161 μmol, 75%, 93.0% purity) as an oil. The crude product was purified by prep-chiral-HPLC to afford desired compound (20.2 mg, 40.9 μmol, 16.7%, 99.5% purity) as a solid.
LCMS: m/z (ES+), [M+H]+=492.2 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, J=4.2 Hz, 1H), 7.95 (s, 1H), 7.60-7.45 (m, 2H), 7.34-7.17 (m, 3H), 5.97 (d, J=7.3 Hz, 1H), 4.04 (d, J=20.1 Hz, 6H), 3.45 (d, J=5.7 Hz, 3H), 2.80 (s, 6H), 2.60 (d, J=12.5 Hz, 1H), 2.18 (s, 1H), 1.93 (d, J=13.1 Hz, 2H), 1.73 (dd, J=27.7, 13.2 Hz, 4H), 1.51 (s, 4H).
To a solution of N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (50 mg, 1 eq, 0.12 mmol) and tetrahydrofuran-2-carboxylic acid (28 mg, 2 eq, 0.24 mmol) in DCM (1 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCl) (34 mg, 1.5 Eq, 0.18 mmol) and 1-hydroxy-1H-benzotriazole (24 mg, 25 μL, 1.5 Eq, 0.18 mmol) and diisopropylethylamine (46 mg, 61 μL, 3 eq, 0.36 mmol). The resulting mixture was stirred for 2 hours at 25 degrees C. The resulting mixture was concentrated under reduced pressure. The crude was purified by reverse flash chromatography followed by prep-chiral-HPLC to afford:
Isomer 1 (12.9 mg, 24.9 μmol, 14%) as a solid.
LCMS: m/z (ES+), [M+H]+=519.20
1H NMR (400 MHz, Methanol-d4) δ 7.93-7.89 (m, 1H), 7.62-7.56 (m, 1H), 7.44 (d, J=8.7 Hz, 1H), 7.37 (td, J=9.2, 8.7, 1.5 Hz, 1H), 4.90 (dd, J=8.2, 5.4 Hz, 1H), 4.03 (d, J=0.9 Hz, 3H), 4.00-3.53 (m, 8H), 3.52-3.37 (m, 2H), 3.34 (s, 7H), 3.01 (d, J=8.7 Hz, 3H), 2.66 (dd, J=12.2, 8.9 Hz, 1H), 2.34-2.14 (m, 2H), 2.14-1.51 (m, 13H), 1.29 (s, 1H).
Isomer 2 (12.7 mg, 24.5 μmol, 13%) as a solid
LCMS: m/z (ES+), [M+H]+=519.2
1H NMR (400 MHz, Methanol-d4) δ 7.93-7.88 (m, 1H), 7.58 (d, J=11.1 Hz, 1H), 7.47-7.32 (m, 2H), 4.94-4.87 (m, 1H), 4.02 (d, J=1.1 Hz, 3H), 3.99-3.88 (m, 2H), 3.88-3.77 (m, 2H), 3.76-3.54 (m, 5H), 3.51-3.38 (m, 2H), 3.01 (d, J=8.5 Hz, 3H), 2.74-2.60 (m, 1H), 2.33-2.14 (m, 2H), 2.05 (td, J=13.4, 12.7, 4.8 Hz, 3H), 1.97-1.55 (m, 11H).
To a stirred solution of N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (100 mg, 1 eq, 238 μmol) in acetonitrile (2 mL) was added 2-chloro-1-(piperidin-1-yl)ethan-1-one (38.4 mg, 1 eq, 238 μmol) N-ethyl-N-isopropylpropan-2-amine (36.9 mg, 1.2 eq, 285 μmol) dropwise and potassium iodide (39.5 mg, 1 eq, 238 μmol) in portions at 25 degrees C. under hydrogen/nitrogen atmosphere. The residue was purified by Prep-TLC followed by Prep-Chiral-HPLC to afford the product (23.5 mg, 42.2 μmol, 21%, 97.9% purity) as a solid.
LCMS: m/z (ES+), [M+H]+=546.4
1H NMR (400 MHz, Methanol-d4) δ 7.93 (d, 1H), 7.60 (d, 1H), 7.47 (d, 1H), 7.38 (dd, 1H), 4.05 (s, 3H), 3.71-3.56 (m, 6H), 3.51-3.44 (m, 1H), 3.42-3.36 (m, 1H), 3.28 (s, 1H), 3.16 (d, 1H), 3.01 (s, 3H), 2.75-2.51 (m, 5H), 2.26 (d, 1H), 2.09 (d, 2H), 1.93-1.81 (m, 4H), 1.69-1.48 (m, 11H).
To a solution of N-((3R,4S)-3-((((1S,4S)-4-(1-methyl-1H-indazol-5-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (80 mg, 1 eq, 0.19 mmol) and HOBt (44 mg, 1.5 Eq, 0.29 mmol) in DCM (2 mL) were added EDC (55 mg, 1.5 Eq, 0.29 mmol) and DIEA (74 mg, 99 μL, 3 eq, 0.57 mmol) and (S)-tetrahydrofuran-3-carboxylic acid (33 mg, 1.5 eq, 0.29 mmol). After stirring for 8 h at 25 degrees C. under a nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The crude was purified by reverse flash chromatography followed by prep-Chiral-HPLC to afford desired product (16 mg, 31 μmol, 16%, 99% purity) as a solid.
LCMS: m/z (ES+), [M+H]+=519.3
1H NMR (400 MHz, Methanol-d4) δ 7.93 (s, 1H), 7.60 (d, 1H), 7.47 (d, 1H), 7.38 (dd, 1H), 4.09-4.02 (m, 3H), 4.00-3.73 (m, 7H), 3.70-3.44 (m, 6H), 3.04 (d, 3H), 2.70 (d, 1H), 2.32-1.99 (m, 5H), 1.97-1.57 (m, 8H).
To a solution of N-((3R,4S)-3-(((4-(1-methyl-1H-benzo[d]imidazol-6-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (130 mg, 1 Eq, 309 μmol) and pyridin-2-yl trifluoromethanesulfonate (84.3 mg, 1.2 eq, 371 μmol) in DMSO (5 mL) was added TEA (93.8 mg, 129 μL, 3 eq, 927 μmol). After stirring for 3 h at 120 degrees C. under a nitrogen atmosphere, the resulting mixture was diluted with H2O (50 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (1×50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude was purified by reverse flash chromatography to afford:
Isomer 1 (7.2 mg, 14 μmol, 40%) as a solid.
LCMS: m/z (ES+), [M+H]+=498
1H NMR (400 MHz, Methanol-d4) δ 8.10-8.02 (m, 2H), 7.61-7.48 (m, 2H), 7.46 (d, 1H), 7.19 (dd, 1H), 6.91-6.84 (m, 1H), 6.70-6.59 (m, 1H), 3.89 (s, 5H), 3.82-3.43 (m, 6H), 3.06 (s, 3H), 2.81-2.68 (m, 1H), 2.38-2.29 (m, 1H), 2.10 (d, 2H), 2.01-1.85 (m, 4H), 1.76-1.58 (m, 4H), 1.41-1.23 (m, 2H), 0.96-0.86 (m, 1H).
Isomer 2 (1 mg, 2 μmol, 20%) as a solid.
LCMS: m/z (ES+), [M+H]+=498
1H NMR (400 MHz, Methanol-d4) δ 8.08 (d, 1H), 7.57 (t, 1H), 7.41 (s, 1H), 7.19 (d, 1H), 6.89 (d, 1H), 6.72-6.63 (m, 1H), 4.64 (s, 2H), 3.89 (s, 3H), 3.75 (dd, 2H), 3.65-3.54 (m, 3H), 3.05 (s, 2H), 2.71 (s, 1H), 2.21 (s, 3H), 1.98 (d, 1H), 1.87 (d, 1H), 1.64 (d, 2H), 1.43 (s, 2H), 1.31 (s, 3H), 0.92 (s, 1H).
To a solution of N-((3R,4S)-3-(((4-(1-methyl-1H-indazol-6-yl)cyclohexyl)oxy)methyl)piperidin-4-yl)methanesulfonamide (100 mg, 1 eq, 238 μmol) and pyridin-2-yl trifluoromethanesulfonate (59.4 mg, 1.1 eq, 262 μmol) in DMSO (5 mL) was added TEA (72.2 mg, 99.4 μL, 3 eq, 713 μmol). After stirring for 3 h at 120 degrees C. under a nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The crude was purified by reverse flash chromatography followed by CHIRAL-HPLC to afford:
LCMS: m/z (ES+), [M+H]+=498
1H NMR (400 MHz, Chloroform-d) δ 8.19 (dd, 1H), 7.92 (s, 1H), 7.63 (d, 1H), 7.53 (s, 1H), 7.40 (s, 1H), 7.04 (d, 1H), 6.78-6.64 (m, 2H), 6.57 (d, 1H), 4.10 (s, 3H), 4.05 (dd, 1H), 3.96 (t, 2H), 3.87 (s, 1H), 3.73 (d, 1H), 3.67 (s, 1H), 3.55 (s, 1H), 3.33 (s, 1H), 3.03 (s, 3H), 2.69 (d, 1H), 2.41 (s, 1H), 2.10 (d, 3H), 2.03 (s, 1H), 1.83 (d, 4H), 1.28 (s, 1H), 0.09 (s, 7H).
Isomer 2 (5.7 mg, 11 μmol, 38%) as a solid.
LCMS: m/z (ES+), [M+H]+=498
1H NMR (400 MHz, Methanol-d4) δ 8.08 (dd, 1H), 7.92 (d, 1H), 7.65 (d, 1H), 7.62-7.55 (m, 1H), 7.48 (s, 1H), 7.36 (s, 1H), 7.08 (dd, 1H), 6.90 (d, 1H), 6.67 (dd, 1H), 4.04 (s, 3H), 3.89-3.79 (m, 2H), 3.75 (dd, 1H), 3.69-3.47 (m, 4H), 3.40 (dd, 1H), 3.05 (s, 3H), 2.70 (t, 1H), 2.22 (d, 3H), 1.99 (d, 2H), 1.87 (q, 2H), 1.74-1.53 (m, 2H), 1.44 (q, 2H), 1.31 (s, 1H).
T-Rex CHO cells stably overexpressing the human orexin-2 receptor (OX2R) were induced overnight with 1 μg/mL of doxycycline in a T225 flask. 24 hours post induction, cells were lifted with accutase and plated into a 384-well proxy plate at 30,000 cells/well. Cells were then treated with different test compounds in 1× stimulation buffer containing 10 mM Hepes, 1 mM CaCl2, 0.5 mM MgCl2, 4.2 mM KCl, 146 mM NaCl, 5.5 mM glucose, and 50 mM LiCl, pH 7.4, for 1 hr at 37 degrees C. Following incubation, the reaction was terminated by the addition of detection mix, which is composed of IP1-d2 and anti-IP1-cryptate diluted in lysis buffer as well as 1× stimulation buffer. The plates were allowed to incubate for 1 hour at room temperature and were then read in the EnVision® multimode plate reader, measuring inositol phosphate levels.
Cisbio IP1 is a cell-based functional assay quantifying the accumulation of inositol monophosphate (IP), a metabolite released as a result of orexin 2 receptor activation through the phospholipase C-Gq signaling pathway. This is a competitive immunoassay in which the IP1 produced by the cells upon receptor activation competes with the IP1 analog coupled to the d2 fluorophore (acceptor) for binding to an anti-IP1 monoclonal antibody labeled with Eu cryptate (donor). The measured HTRF-FRET based signal is inversely proportional to the IP1 concentration produced.
The EC50 values reported in Table 2 were obtained according to the human OX2R IP1 assay described above. Data are the mean EC50 values±S.E.M.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
This application is a continuation of International Application No. PCT/US23/25385, which designated the United States and was filed on Jun. 15, 2023, published in English, which claims the benefit of U.S. Provisional patent application Ser. No. 63/353,998, filed on Jun. 21, 2022. The entire contents of the above-identified applications are herein incorporated by reference.
| Number | Date | Country | |
|---|---|---|---|
| 63353998 | Jun 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US23/25385 | Jun 2023 | WO |
| Child | 18983714 | US |
